WO2013135165A1 - Synthetic intermediate of entecavir and method for preparing same - Google Patents

Synthetic intermediate of entecavir and method for preparing same Download PDF

Info

Publication number
WO2013135165A1
WO2013135165A1 PCT/CN2013/072458 CN2013072458W WO2013135165A1 WO 2013135165 A1 WO2013135165 A1 WO 2013135165A1 CN 2013072458 W CN2013072458 W CN 2013072458W WO 2013135165 A1 WO2013135165 A1 WO 2013135165A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
reagent
chloride
reaction
Prior art date
Application number
PCT/CN2013/072458
Other languages
French (fr)
Chinese (zh)
Inventor
郑志国
Original Assignee
浙江奥翔药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江奥翔药业有限公司 filed Critical 浙江奥翔药业有限公司
Publication of WO2013135165A1 publication Critical patent/WO2013135165A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/36Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Definitions

  • the present invention relates to a synthetic intermediate for a medicament and a process for the preparation thereof, and in particular to a novel synthetic intermediate for the preparation of entecavir and a process for the preparation of the intermediate.
  • Entecavir is the third anti-hepatitis B virus (HBV) drug listed after lamivudine and adefovir dipivoxil, and is the most potent anti-HBV drug currently on the market.
  • the anti-HBV effect of entecavir is 100 times that of lamivudine and more than 30 times that of adefovir dipivoxil; its side effects are very low, the selection index is greater than 8000, and the HBV virus resistant to lamivudine is also very Good curative effect is one of the most important drugs for the treatment of hepatitis B.
  • entecavir contains a chiral five-membered ring and a guanine nucleus.
  • the chiral five-membered carbocyclic ring has three chiral centers and one methylene ring outside the ring.
  • the structure is more complicated, although it has been reported that There are few synthetic methods, but existing synthetic methods have difficulties in preparation. At present, there are mainly the following methods for preparing entecavir.
  • the preparation method of entecavir is disclosed in Chinese patent ZL91110831.9 and international application WO98/09964.
  • the method comprises the steps of: reacting cyclopentadiene as a raw material, and sequentially reacting with chloromethylbenzyl ether and a di-enyl borane complex (Ipc 2 BH) prepared from (+)- ⁇ -olefin to obtain a chiral intermediate iii.
  • Vi is protected by a single p-methoxytriphenylchloromethane (MMTC1) protecting group, and then oxidized to a keto group by the Dess-Martin reagent to give viii.
  • Viii is subjected to a methyleneation reaction under the action of Nysted reagent and titanium tetrachloride to obtain ix.
  • the problems in the preparation method should be complicated, and some reagents are expensive.
  • the starting materials require expensive chiral boron reagents, and some intermediates are difficult to synthesize, the reaction conditions are harsh, and the final debenzylation is highly toxic.
  • the boron trichloride is highly polluting to the environment and requires high equipment.
  • WO2010/074534 uses the following reaction to prepare entecavir via Intermediate II, but the reaction conditions are harsh, the reagents used are expensive, and it is difficult to apply to industrial production.
  • alkyl denotes a straight or branched monovalent saturated hydrocarbon group consisting of carbon and hydrogen atoms.
  • Cw alkyl means a branched or straight-chain alkyl group having 1 to 6 ⁇ , such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, Is the base.
  • alkylene denotes a straight or branched divalent saturated hydrocarbon group consisting of carbon and hydrogen atoms.
  • d_ 6 alkylene denotes a ⁇ 1-6, child Branched or linear alkylene, such as methylene, ethylene, and the like.
  • alkane alone or in combination with other groups, denotes a radical R,-0-, wherein R is an alkyl radical as defined above.
  • d- 6 alkoxy denotes a radical R,-0-, wherein R, Is as described above
  • Halogen means fluorine, chlorine, bromine or iodine.
  • Haloalkyl means an alkyl group as defined above substituted by one or more halogens, for example trifluoromethyl.
  • Aryl means a monocyclic or fused bicyclic aromatic ring containing a carbon atom.
  • C 5 _ 1Q aryl means an aryl group having 5 to 10 carbon atoms.
  • the C 5 _ 1() aryl group can be phenyl or naphthyl.
  • Alkyl means an alkyl group as described above substituted with an aryl group as described above.
  • Alkyloxy means an alkoxy group as described above substituted with an aryl group as described above.
  • Grubbs catalyst refers to a Grubbs catalyst that catalyzes the metathesis of olefins.
  • the first generation of Grubbs catalyst is, for example, benzylidene-bis(tricyclohexylphosphine) dichloro ruthenium
  • the second generation catalyst of Grubbs is, for example, benzylidene-[1,3-di(2,4,6-three) Methylphenyl)-2-imidazolinium iododi-(tricyclohexylphosphine) ruthenium.
  • Dioxane wire means "compound 2, wherein R" are each independently of formula NR 6 alkyl or C 3 _ 7 cycloalkyl is selected D_, e.g. N, N- diisopropylamine, N, N- Dicyclohexylamine.
  • the dioxane further includes two R" together with the N atom to which they are attached forms an optionally substituted heterocyclic ring, for example, 2,2,6,6-tetramethylhexahydropyridine.
  • the present invention provides a novel process for the preparation of intermediate II in the entecavir synthesis of formula I which has a higher yield, lower cost and less environmental pollution than existing processes.
  • the invention provides a novel method of synthesizing intermediate II, characterized by Asymmetric catalytic reaction
  • the chiral five-membered carbocyclic intermediate II of entecavir was prepared in high yield.
  • R is a hydroxy protecting group selected from the group consisting of: (i) an alkyl group, (ii) an aralkyl group such as a benzyl group, (iii) an alkoxyalkylene group such as an alkoxymethylene group such as MeOCH 2 -, (iv An aralkoxyalkylene group, such as an aralkylmethyl group, such as a BnOCH 2 -, or a (V) silane group, such as a triphenyl 3 ⁇ 4, a triisopropylsilyl group, a tert-butyldimethyl group, a tertiary Butyl diphenyl ⁇ ⁇ group;
  • R is a hydroxy protecting group, selected from: (i) an aralkyl group such as a trityl group, or (ii) a silane group, such as a triphenyl group, a triisopropyl group, a t-butyl dimethyl group: Uncle Ding ⁇ ! Benzene: base; the method comprises the following steps:
  • compound 6 is epoxy-opened to form intermediate II under the action of a dialkylaluminum chloride reagent and lithium N,N-dialkylamine,
  • the reaction solvent may be a polar or non-polar aprotic solvent, and preferred solvents include, but are not limited to, tetrahydrofuran, dichloromethane, chloroform, dimethylformamide, dioxane, diethyl ether.
  • the reaction solvent may be dichloromethane, 1,2-dichloroethane, chloroform, tetrahydrofuran, benzene or toluene.
  • the catalyst for the reaction may be Grubbs first or second generation catalyst in an amount of from 0.1 to 20 eq%, and the reaction temperature is from room temperature to 120 * €.
  • a coordination reagent of metal vanadium is used as a catalyst, such as VO(acac) 2
  • the epoxidizing reagent may be t-butyl hydroperoxide, hydrogen peroxide, m-chloroperoxybenzoic acid, peroxybenzoic acid.
  • the reaction solvent can be dichloromethane, 1,2-dichloroethane, chloroform, tetrahydrofuran, benzene, toluene and other solvents; reaction temperature is 0" € ⁇ room temperature, reaction time is 1 ⁇ 48 hours.
  • R is selected from the group consisting of BnOCH 2 -, MeOCH 2 -, t-Bu(Me) 2 Si -, i-Pr 3 Si- and t-BuPh 2 Si - X is a halogen, such as C1;
  • the base used in the reaction may be triethylamine, diisopropylethylamine, DBU, imidazole, etc.;
  • the reaction solvent may be dichloromethane, 1,2-dichloroethane, Chloroform, tetrahydrofuran, benzene, toluene, dimethylformamide;
  • the temperature should be -10*C ⁇ 45X.
  • the dialkyl aluminum chloride reagent is, for example, diethylaluminum chloride
  • the N,N-dialkyllithium is prepared in situ from the corresponding dialkylamine by reaction with butyllithium, wherein the dialkyl group
  • the amine is selected from the group consisting of N,N-diisopropylamine, N,N-dicyclohexylamine and 2,2,6,6-tetramethylhexahydropyridine, preferably 2,2,6,6-tetramethyl-6 Hydropyridine; reaction temperature is -20" € ⁇ room temperature, reaction time is 1 ⁇ 48 hours.
  • the intermediate product can be prepared by directly carrying out the subsequent reaction using the reaction product obtained in any of the steps c) to e) as a raw material.
  • the compound of the formula (4) can be used as a raw material and the steps d) to f) as described above can be used to prepare the intermediate II, or the compound of the formula (5) can be used as a raw material and the step e) as described above can be carried out. f) to prepare intermediate II, and the like.
  • R is a hydroxy protecting group selected from the group consisting of: (i) an alkyl group, (ii) an aralkyl group such as a benzyl group, (iii) an alkoxyalkylene group such as an alkoxymethylene group such as MeOCH 2 -, (iv ) aralkyloxy alkylene, e.g. methylene aralkyl * ⁇ , as BnOCH 2 -, or (V) silyl, such as triphenyl silicon, triisopropylsilyl, tert-butyldimethyl , tert-butyl diphenyl ⁇ ⁇ group;
  • R is a hydroxy protecting group, selected from: (i) an aralkyl group such as a trityl group, or (ii) a silane group, such as a triphenyl group, a triisopropyl J3 ⁇ 4 group, a t-butyl dimethyl group , tert-butyl benzene ⁇ ⁇ base; the method comprises the following steps:
  • X is a halogen or a cyano group
  • compound 6 is epoxy-opened to form intermediate II under the action of a dialkylaluminum chloride reagent and lithium N,N-dialkylamine,
  • the reaction solvent may be a polar or non-polar aprotic solvent, and preferred solvents include, but are not limited to, tetrahydrofuran, dichloromethane, chloroform, dimethylformamide, dioxane, diethyl ether.
  • the reaction solvent may be tetrahydrofuran, diethyl ether, dibutyl ether or dioxane.
  • a preferred solvent may be tetrahydrofuran.
  • the reaction time is from 1 to 48 hours, and the reaction temperature is from -78 to room temperature.
  • the cuprous halide reagent can be Cul, CuBr or CuBr.Me 2 S.
  • Compound 1 can be produced according to the method of the literature (Angew. Chem. Int. Ed. 2010, 49, 881).
  • the primary hydroxyl protecting agent R, X is selected from the group consisting of triphenylsilyl chloride, triisopropylsilyl chloride, tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride, three Phenylchloromethane.
  • the reaction solvent may be dimethylformamide, dichloromethane, chloroform or toluene.
  • the base includes an organic base such as triethylamine,
  • the intermediate product can be prepared by directly carrying out the subsequent reaction using the reaction product obtained in any of steps a) to e) as a raw material.
  • a compound of the formula (4) can be used as a raw material and carried out as described above.
  • the intermediates II are prepared by the steps d) to f), or the intermediates of the formula (2) are used as starting materials and the steps b) to f) as described above are carried out to prepare the intermediate II, and the like.
  • the invention provides a compound of the formula V:
  • R is a hydrogen or hydroxy protecting group selected from: (i) an alkyl group, (ii) an aralkyl group such as a benzyl group, (iii) an alkoxyalkylene group such as an alkylene group such as MeOCH 2 -, (iv An aralkoxyalkylene group, such as an aralkyloxymethylene group, such as a BnOCH 2 -, or a (V) silane group, such as triphenyl&, triisopropylsilyl, tert-butylmethyl, tert-butyl ⁇ phenyl;
  • R which is a hydroxy protecting group, is selected from the group consisting of: (i) an aralkyl group such as a trityl group, or (ii) a silane group such as a triphenyl group, a triisopropyl group, a tert-butyl group; Base, tert-butyl benzene ⁇ ⁇ base.
  • the compound of formula V is selected from the group consisting of:
  • the invention provides a method of preparing a compound of formula V,
  • R is a hydrogen or hydroxy protecting group selected from the group consisting of: (i) an alkyl group, (ii) an aralkyl group such as a benzyl group, (iii) an alkoxyalkylene group such as an alkoxymethylene group such as MeOCH 2 -, (iv) an aralkoxyalkylene group, such as an aralkyloxymethylene group, such as a BnOCH 2 -, or a (V) silane group, such as a triphenylsilyl group, a triisopropylsilyl group, a tert-butyl group ⁇ , ⁇ ;
  • R which is a hydroxy protecting group, is selected from the group consisting of: (i) an aralkyl group such as a trityl group, or (ii) a silane group such as triphenyl, triisopropyl, tert-butyldimethyl, and tert-butylbenzene.
  • the method includes the following steps:
  • X is a halogen or an aryl group
  • R is hydrogen, R, as defined above,
  • R and R as defined above, and R is not hydrogen.
  • reaction conditions of steps a), b), c), d) and e) are as described above.
  • the intermediate product can be prepared by directly carrying out the subsequent reaction using the reaction product obtained in any of the steps a) to d) as a raw material.
  • the compound of the formula (4) can be used as a raw material and the steps d) to e) as described above can be carried out to prepare the compound V, or the compound of the formula (2) can be used as a raw material and the steps b) to e as described above can be carried out.
  • the invention provides a compound of formula 4:
  • R is a hydroxy protecting group selected from the group consisting of: (i) an aralkyl group such as a trityl group, or (ii) a silane group such as triphenyl & triisopropyl, tert-butyl & tert-butyldiphenyl ⁇ ⁇ ⁇ .
  • the invention provides a method of preparing a compound of formula 4,
  • R is a hydroxy protecting group selected from the group consisting of: (i) an aralkyl group such as a trityl group, or (ii) a silane group such as a triphenyl group: a trisyl group, a triisopropyl group, a tert-butyl group! M ⁇ : base, tert-butyl diphenyl ⁇ J3 ⁇ 4 base, the method comprises the following steps:
  • X is a halogen or an aryl group
  • reaction conditions of steps a), b), c) are as described above. It will be understood by those skilled in the art that in the above method of synthesizing the compound 4, the reaction product obtained in any of the steps a) to b) can be directly used as a starting material to carry out the subsequent reaction to prepare the intermediate II.
  • compound 4 can be prepared by using the compound of formula (3) as a starting material and carrying out step c) as described above, or using the compound of formula (2) as a starting material and carrying out steps b) to c) as described above. Compound 4, and so on.
  • the invention provides
  • R is a hydrogen or hydroxy protecting group selected from: (i) an aralkyl group such as a trityl group, or (ii) a silane group such as a triphenyl JJ3 ⁇ 4 group, a triisopropyl group, a tert-butyl group JJ3 ⁇ 4 base, tert-butyldiphenyl group.
  • the compound of formula III is selected from the group consisting of:
  • the invention provides a method
  • R is a hydrogen or hydroxy protecting group selected from the group consisting of: (i) an aralkyl group such as a trityl group, or (ii) a silane group such as a triphenyl group, a triisopropyl group: a tert-butyl group M ⁇ 3 ⁇ 4 base, tert-butyl diphenyl silicon,
  • the method includes the following steps:
  • X is a halogen or a cyano group
  • R is as defined above, and R is not hydrogen and X is halogen.
  • reaction conditions of steps a), b) are as described above.
  • the invention provides a method of synthesizing entecavir of formula I via intermediate II as described above, characterized in that entecavir is obtained by the Mitsunobu reaction of the intermediate II with a guanine derivative.
  • the method for synthesizing entecavir of formula I comprises the steps of: c) subjecting compound 3 to the cyclic compound 4 via olefin metathesis in the presence of a Grubbs catalyst,
  • R is as defined by the compound of formula II above,
  • X is a compound, R and R, as defined by the compound of formula II above,
  • compound 6 is epoxy-opened to form intermediate II under the action of a dialkylaluminum chloride reagent and lithium N,N-dialkylamine,
  • R and R are as defined by the compound of formula II above,
  • the reaction solvent may be dichloromethane, 1,2-dichloroethane, chloroform, tetrahydrofuran, benzene or toluene.
  • the catalyst for the reaction may be Grubbs first or second generation catalyst in an amount of from 0.1 to 20 eq%, and the reaction temperature is from room temperature to 120 " €.
  • a coordination reagent of metal vanadium is used as a catalyst, such as VO(acac) 2
  • the epoxidizing reagent may be t-butyl hydroperoxide, hydrogen peroxide, m-chloroperoxybenzoic acid, peroxybenzoic acid.
  • the reaction solvent can be dichloromethane, 1,2-dichloroethane, chloroform, tetrahydrofuran, benzene, toluene and other solvents; reaction temperature is 0X ⁇ room temperature, reaction time is 1 ⁇ 48 hours .
  • R is selected from the group consisting of BnOCH 2 -, MeOCH 2 -, t-Bu(Me) 2 Si -, i-Pr 3 Si- and t-BuPh 2 Si - X is a halogen, such as C1;
  • the base used in the reaction may be triethylamine, diisopropylethylamine, DBU, imidazole, etc.;
  • the reaction solvent may be dichloromethane, 1,2-dichloroethane, chloroform , tetrahydrofuran, benzene, toluene, dimethylformamide; reaction temperature is -10*C ⁇ 45X.
  • the dialkyl aluminum chloride reagent is, for example, diethylaluminum chloride
  • the N,N-dialkyllithium is prepared in situ from the corresponding dialkylamine by reaction with butyllithium, wherein the dialkyl group
  • the amine is selected from the group consisting of N,N-diisopropylamine, N,N-dicyclohexylamine and 2,2,6,6-tetramethylhexahydropyridine, preferably 2,2,6,6-tetramethyl-6 Hydropyridine; reaction temperature is -20" € ⁇ room temperature, reaction time is 1 ⁇ 48 hours.
  • the Mitsunobu reaction reagent is a phosphine catalyst such as triphenylphosphine and diethyl azodicarboxylate or diisopropyl azodicarboxylate
  • the reaction solvent may be an aprotic solvent such as tetrahydrofuran, dichloromethane, or Oxycyclohexane, diethyl ether, toluene, etc.; tetrahydrofuran is preferred.
  • the reaction temperature is -23 "C ⁇ room temperature.
  • the reaction time is 1 to 48 hours.
  • the reaction solvent is an aprotic or protic solvent such as tetrahydrofuran, dioxane, methanol, ethanol or the like
  • the acid used is a mineral acid such as hydrochloric acid, sulfuric acid or the like.
  • the reaction temperature is room temperature ⁇ 120" €.
  • the reaction time is 3 to 48 hours.
  • the reaction product obtained in any of the steps c) to g ) can be directly used as a raw material to carry out the subsequent reaction to prepare entecavir of the formula (I).
  • a compound of the formula (4) can be used as a raw material and carried out as described above.
  • the method of synthesizing entecavir of Formula I comprises the steps of: a) intermediate compound 1 being reacted with an isopropenol Grignard reagent in the presence of a cuprous halide to provide a compound 2
  • X is a halogen or an aryl group
  • compound 6 is epoxy-opened to form intermediate II under the action of a dialkylaluminum chloride reagent and lithium N,N-dialkylamine,
  • the reaction solvent is a polar or non-polar solvent, and preferred solvents are tetrahydrofuran, dichloromethane, chloroform, methanol, ethanol, dimethylformamide, dioxane, diethyl ether.
  • the reaction solvent may be tetrahydrofuran, diethyl ether, dibutyl ether or dioxane.
  • a preferred solvent may be tetrahydrofuran.
  • the reaction time is from 1 to 48 hours, and the reaction temperature is from -78 to room temperature.
  • the cuprous halide reagent can be Cul, CuBr or CuBr.Me 2 S.
  • Compound 1 can be produced according to the method of the literature (Angew. Chem. Int. Ed. 2010, 49, 881).
  • the primary hydroxyl protecting agent R, X is selected from the group consisting of triphenylsilyl chloride, triisopropylsilyl chloride, tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride, three Phenylchloromethane.
  • the reaction solvent may be dimethylformamide, dichloromethane, chloroform or toluene.
  • the base includes an organic base such as triethylamine,
  • the synthetic route of entecavir is as follows,
  • the synthetic route of entecavir is as follows,
  • the reaction product obtained in any of steps a) to g ) can be used as a raw material to directly carry out the subsequent reaction to prepare entecavir of the formula (I).
  • the compound of the formula (4) can be used as a raw material and the steps d) to h) as described above can be carried out to prepare entecavir of the formula (I), or the compound of the formula (2) can be used as a raw material and the steps as described above can be carried out.
  • Example 7 According to the similar method of the above Example 7, the secondary hydroxysilicon-protected compound prepared in Example 5 was used to obtain the following product in a yield of 92.5%.
  • the novel preparation method provided by the invention is easy to purify, the quality is controllable, and the raw materials are easy to obtain, the price is cheap, and the production cost is better reduced.

Abstract

The present invention is related to a synthetic intermediate of entecavir and a method for preparing same, and particularly, related to a synthetic intermediate of Formula II for preparing entecavir, a method for preparing the intermediate, and a method for preparing entecavir by using the intermediate of Formula II, wherein R and R' are defined in the specification.

Description

恩替卡韦的合成中间体及其制备方法 技术领域  Synthetic intermediate of entecavir and preparation method thereof
本发明涉及药物的合成中间体及其制备方法, 具体而言, 涉及用于制 备恩替卡韦的新的合成中间体以及所述中间体的制备方法。
Figure imgf000002_0001
The present invention relates to a synthetic intermediate for a medicament and a process for the preparation thereof, and in particular to a novel synthetic intermediate for the preparation of entecavir and a process for the preparation of the intermediate.
Figure imgf000002_0001
恩替卡韦,即下面式 I所示的化合物, 2-氨基 -1,9-二氢 -9-[(lS,3R,4S)-4- 羟基 -3- (羟甲基) -2-亚甲基环戊基】-6H-嘌呤 -6-酮,是一种新的核苷类抗病毒 药。  Entecavir, a compound of the formula I below, 2-amino-1,9-dihydro-9-[(lS,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylene Cyclopentyl]-6H-indol-6-one is a new nucleoside antiviral drug.
Figure imgf000002_0002
Figure imgf000002_0002
恩替卡韦是继拉米夫定和阿德福韦酯后上市的第三个抗乙型肝炎病毒 (HBV)的药物,也是目前上市的最高效的抗 HBV药物。恩替卡韦的抗 HBV 作用是拉米夫定的 100倍, 是阿德福韦酯的 30多倍; 它的副作用很低, 选 择指数大于 8000, 并且对拉米夫定耐药的 HBV病毒也具有很好的疗效, 是目前治疗乙肝的最重要的药物之一。  Entecavir is the third anti-hepatitis B virus (HBV) drug listed after lamivudine and adefovir dipivoxil, and is the most potent anti-HBV drug currently on the market. The anti-HBV effect of entecavir is 100 times that of lamivudine and more than 30 times that of adefovir dipivoxil; its side effects are very low, the selection index is greater than 8000, and the HBV virus resistant to lamivudine is also very Good curative effect is one of the most important drugs for the treatment of hepatitis B.
恩替卡韦的结构中含有一个手性五元破环和鸟嘌呤母核, 其中手性五 元碳环上具有三个手性中心和一个环外的亚甲基, 结构比较复杂, 虽然已 报道了不少合成方法, 但现有的合成方法在制备中均有困难。 目前关于制 备恩替卡韦的方法主要有以下几种。  The structure of entecavir contains a chiral five-membered ring and a guanine nucleus. The chiral five-membered carbocyclic ring has three chiral centers and one methylene ring outside the ring. The structure is more complicated, although it has been reported that There are few synthetic methods, but existing synthetic methods have difficulties in preparation. At present, there are mainly the following methods for preparing entecavir.
中国专利 ZL91110831.9和国际申请 WO98/09964公开了恩替卡韦的 制备方法。 该方法以环戊二烯为原料, 依次与氯甲基苄甲醚、 由 (+)-α-象烯 制备的二象烯硼烷配合物 (Ipc2BH)反应制得手性中间体 iii, 再在乙酰丙酮 氧化钒 [VO(acac)2】催化下经过氧化叔丁醇环氧化得到 iv。 iv在氢化钠和碘 化四丁铵作用下与溴苄反应得 v。 V在氢化锂作用下和 6-苄氧基 -2-氨基嘌 呤反应得 vi。 vi经单对甲氧基三苯基氯甲烷 (MMTC1)保护 基得 vii,然后 在 Dess-Martin试剂作用下将羟基氧化成酮基得 viii。 viii在 Nysted试剂和 四氯化钛的作用下进行亚甲基化反应得 ix。 ix 与盐酸反应脱去氨基上的 MMT和嘌呤环上的苄基得 X,最后在三氯化硼作用下脱去碳环羟基上的苄 基得恩替卡韦 (式 I化合物)。 该方法如以下流程所示。 The preparation method of entecavir is disclosed in Chinese patent ZL91110831.9 and international application WO98/09964. The method comprises the steps of: reacting cyclopentadiene as a raw material, and sequentially reacting with chloromethylbenzyl ether and a di-enyl borane complex (Ipc 2 BH) prepared from (+)-α-olefin to obtain a chiral intermediate iii. Acetylacetone Oxidation of oxidized t-butanol to give iv under the catalysis of vanadium oxide [VO(acac) 2 ]. Iv reacted with benzyl bromide under the action of sodium hydride and tetrabutylammonium iodide to give v. V is reacted with 6-benzyloxy-2-aminopurine under the action of lithium hydride to give vi. Vi is protected by a single p-methoxytriphenylchloromethane (MMTC1) protecting group, and then oxidized to a keto group by the Dess-Martin reagent to give viii. Viii is subjected to a methyleneation reaction under the action of Nysted reagent and titanium tetrachloride to obtain ix. Ix is reacted with hydrochloric acid to remove the MMT from the amino group and the benzyl group on the anthracene ring to obtain X. Finally, the benzyl entecavir (the compound of the formula I) on the carbocyclic hydroxyl group is removed by the action of boron trichloride. This method is shown in the following flow.
Figure imgf000003_0001
Figure imgf000003_0001
该制备方法存在的问题^ ^应复杂, 部分试剂成本高, 例如起始原料 需用价格昂贵的手性硼试剂, 而且部分中间体合成的难度大, 反应条件苛 刻, 最终脱苄基采用剧毒的三氯化硼, 对环境污染较大, 对设备要求高。  The problems in the preparation method should be complicated, and some reagents are expensive. For example, the starting materials require expensive chiral boron reagents, and some intermediates are difficult to synthesize, the reaction conditions are harsh, and the final debenzylation is highly toxic. The boron trichloride is highly polluting to the environment and requires high equipment.
另外, 也有先合成关键中间体 II, 再与鸟嘌呤环经 Mitsunobu反应得 到恩替卡韦的方法, 但现有的方法中制备中间体 II的成本高, 反应复杂, 缺乏应用价值。例如,在施贵宝公司的专利申请 (公开号为 WO 2004/052310 A2)中公开了一种以价格昂贵的 Corey 内酯为原料的合成方法, 如以下流 程所示。 In addition, the key intermediate II is synthesized first, and then reacted with the guanine ring by Mitsunobu. The method of entecavir, but the preparation of intermediate II in the existing method is costly, complicated, and lacks application value. For example, a synthetic method using expensive Corey lactone as a raw material is disclosed in the patent application of the company (Publication No. WO 2004/052310 A2), as shown in the following scheme.
Figure imgf000004_0001
此外, WO2010/074534利用下述反应经中间体 II制备恩替卡韦,但反 应条件苛刻, 使用的试剂昂贵, 难以应用于工业生产。
Figure imgf000005_0001
Figure imgf000004_0001
Further, WO2010/074534 uses the following reaction to prepare entecavir via Intermediate II, but the reaction conditions are harsh, the reagents used are expensive, and it is difficult to apply to industrial production.
Figure imgf000005_0001
因此, 目前需要开发一种新的制备关键中间体 II的方法, 其能够克服 现有方法的问题, 具有较高的收率、 成 ^低并 环境污染较小。 发明内容  Therefore, there is a need to develop a new method for preparing a key intermediate II which overcomes the problems of the prior art methods, has a high yield, is low, and has less environmental pollution. Summary of the invention
在本发明中, 下列术语具有以下所述的含义:  In the present invention, the following terms have the meanings described below:
单独或与其他基团组合的术语 "烷基" 表示由碳和氢原子组成的直链 或支链的单价饱和烃基团。 "Cw烷基" 表示具有 1至 6个^^子的支链 或直链烷基, 例如甲基、 乙基、 正丙基、 异丙基、 正丁基、 仲丁基、 叔丁 基、 正己基。  The term "alkyl", alone or in combination with other groups, denotes a straight or branched monovalent saturated hydrocarbon group consisting of carbon and hydrogen atoms. "Cw alkyl" means a branched or straight-chain alkyl group having 1 to 6 ^, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, Is the base.
单独或与其他基团组合的术语 "亚烷基" 表示由碳和氢原子组成的直 链或支链的二价饱和烃基团。 "d_6亚烷基" 表示具有 1至 6个^、子的 支链或直链亚烷基, 例如亚甲基、 亚乙基等。 The term "alkylene", alone or in combination with other groups, denotes a straight or branched divalent saturated hydrocarbon group consisting of carbon and hydrogen atoms. "d_ 6 alkylene" denotes a ^ 1-6, child Branched or linear alkylene, such as methylene, ethylene, and the like.
单独或与其他基团组合的术语 "烷 表示基团 R,-0-, 其中 R,是 如上所述的烷基。 "d_6烷氧基" 表示基团 R,-0-, 其中 R,是如上所述的The term "alkane, alone or in combination with other groups, denotes a radical R,-0-, wherein R is an alkyl radical as defined above. "d- 6 alkoxy" denotes a radical R,-0-, wherein R, Is as described above
Ci-6 基。 Ci-6 base.
"卤素" 是指氟、 氯、 溴或碘。  "Halogen" means fluorine, chlorine, bromine or iodine.
"卤代烷基" 表示被一个或多个卤素取代的如上所定义的烷基, 例如 三氟甲基。  "Haloalkyl" means an alkyl group as defined above substituted by one or more halogens, for example trifluoromethyl.
"芳基" 是指含有碳原子的单环或稠合双环的芳香环。 "C5_1Q芳基" 是指含有 5-10个碳原子的芳基。 例如, C5_1()芳基可以是苯基或萘基。 "Aryl" means a monocyclic or fused bicyclic aromatic ring containing a carbon atom. "C 5 _ 1Q aryl" means an aryl group having 5 to 10 carbon atoms. For example, the C 5 _ 1() aryl group can be phenyl or naphthyl.
"芳烷基" 是指被如上所述的芳基取代的如上所述的烷基。  "Aralkyl" means an alkyl group as described above substituted with an aryl group as described above.
"芳烷氧基" 是指被如上所述的芳基取代的如上所述的烷氧基。  "Aralkyloxy" means an alkoxy group as described above substituted with an aryl group as described above.
"Grubbs催化剂" 是指催化烯烃复分解反应的 Grubbs催化剂, "Grubbs catalyst" refers to a Grubbs catalyst that catalyzes the metathesis of olefins.
Grubbs 第一代催化剂是例如苯亚甲基-二 (三环己基膦)二氯合钌, Grubbs 第二代催化剂是例如苯亚甲基 -[1,3-二 (2,4,6-三甲基苯基) -2-咪唑啉亚基卜二 氯- (三环己基膦)合钌。 The first generation of Grubbs catalyst is, for example, benzylidene-bis(tricyclohexylphosphine) dichloro ruthenium, and the second generation catalyst of Grubbs is, for example, benzylidene-[1,3-di(2,4,6-three) Methylphenyl)-2-imidazolinium iododi-(tricyclohexylphosphine) ruthenium.
"二烷絲" 是指式 NR"2的化合物, 其中 R"各自独立地选自 d_6 烷基或 C3_7环烷基, 例如 N,N-二异丙基胺、 N,N-二环己基胺。 在本文中, "二烷 还包括两个 R"与它们所连接的 N原子一起形成任选地践 基取代的杂环的情况, 例如 2,2,6,6-四甲基六氢吡啶。 "Dioxane wire" means "compound 2, wherein R" are each independently of formula NR 6 alkyl or C 3 _ 7 cycloalkyl is selected D_, e.g. N, N- diisopropylamine, N, N- Dicyclohexylamine. Herein, the case where "the dioxane further includes two R" together with the N atom to which they are attached forms an optionally substituted heterocyclic ring, for example, 2,2,6,6-tetramethylhexahydropyridine.
本发明提供了用于式 I的恩替卡韦合成中的中间体 II的新制备方法, 其相对于现有方法具有较高的收率、 成本较低并且对环境污染较小。  The present invention provides a novel process for the preparation of intermediate II in the entecavir synthesis of formula I which has a higher yield, lower cost and less environmental pollution than existing processes.
R,R,
Figure imgf000006_0001
Figure imgf000006_0001
一方面, 本发明提供一种新的合成中间体 II的方法, 其特征在于通过 不对称催化反应高收率地制备恩替卡韦的手性五元碳环中间体 II。 In one aspect, the invention provides a novel method of synthesizing intermediate II, characterized by Asymmetric catalytic reaction The chiral five-membered carbocyclic intermediate II of entecavir was prepared in high yield.
在一个实施方案中, 提供了 成方法:  In one embodiment, a method is provided:
Figure imgf000007_0001
Figure imgf000007_0001
R是羟基保护基, 选自: (i)烷基, (ii)芳烷基例如苄基, (iii)烷氧基亚 烷基, 例如烷氧基亚甲基, 如 MeOCH2-, (iv)芳烷氧基亚烷基, 例如芳烷 甲基,如 BnOCH2-,或 (V)硅烷基,例如三苯基¾、三异丙基硅基、 叔丁基二甲^ ^基、 叔丁基二苯^ ^基; R is a hydroxy protecting group selected from the group consisting of: (i) an alkyl group, (ii) an aralkyl group such as a benzyl group, (iii) an alkoxyalkylene group such as an alkoxymethylene group such as MeOCH 2 -, (iv An aralkoxyalkylene group, such as an aralkylmethyl group, such as a BnOCH 2 -, or a (V) silane group, such as a triphenyl 3⁄4, a triisopropylsilyl group, a tert-butyldimethyl group, a tertiary Butyl diphenyl ^ ^ group;
R,是羟基保护基, 选自: (i)芳烷基例如三苯甲基, 或 (ii)硅烷基, 例如 三苯^:基、 三异丙 基、 叔丁基二甲^:基、 叔丁^!苯^:基; 该方法包括以下步骤:  R, is a hydroxy protecting group, selected from: (i) an aralkyl group such as a trityl group, or (ii) a silane group, such as a triphenyl group, a triisopropyl group, a t-butyl dimethyl group: Uncle Ding ^! Benzene: base; the method comprises the following steps:
c)将化合物 3在 Grubbs催化剂存在下, 经烯烃复分解反应得到环状 化合物 4,  c) the compound 3 is subjected to olefin metathesis reaction in the presence of a Grubbs catalyst to obtain a cyclic compound 4,
Figure imgf000007_0002
Figure imgf000007_0002
其中 R,如上文所定义,  Where R, as defined above,
d) 将化合物 4 与环氧化试剂在金属钒试剂催化下立体选择性地得到 环氧化中间体 5,  d) stereoselectively obtaining an epoxidation intermediate 5 by catalyzing the compound 4 with an epoxidation reagent under a metal vanadium reagent,
Figure imgf000007_0003
Figure imgf000007_0003
e)将化合物 5的仲醇进行保护得到化合物 6,
Figure imgf000008_0001
e) protecting the secondary alcohol of compound 5 to give compound 6,
Figure imgf000008_0001
其中 X为卤素, R和 R,如上文所定义,  Wherein X is halogen, R and R, as defined above,
f)化合物 6在二烷基氯化铝试剂和 N,N-二烷基胺锂作用下环氧开环形 成中间体 II,  f) compound 6 is epoxy-opened to form intermediate II under the action of a dialkylaluminum chloride reagent and lithium N,N-dialkylamine,
Figure imgf000008_0002
Figure imgf000008_0002
其中 R和 R,如上文所定义。  Where R and R are as defined above.
在上述的反应中, 反应溶剂可以是极性或非极性的非质子溶剂, 优选 的溶剂包括但不限于四氢呋喃、 二氯甲烷、 氯仿、 二甲基甲酰胺、 二氧六 环、 乙醚。  In the above reaction, the reaction solvent may be a polar or non-polar aprotic solvent, and preferred solvents include, but are not limited to, tetrahydrofuran, dichloromethane, chloroform, dimethylformamide, dioxane, diethyl ether.
在步骤 c中,反应溶剂可为二氯甲烷、 1,2-二氯乙烷、氯仿、四氢呋喃、 苯、 甲苯。 反应的催化剂可以为 Grubbs第一代或第二代催化剂, 用量为 0.1-20 eq%, 反应温度为室温〜 120 *€。  In the step c, the reaction solvent may be dichloromethane, 1,2-dichloroethane, chloroform, tetrahydrofuran, benzene or toluene. The catalyst for the reaction may be Grubbs first or second generation catalyst in an amount of from 0.1 to 20 eq%, and the reaction temperature is from room temperature to 120 * €.
在步骤 d中, 使用金属钒的配位试剂作为催化剂, 例如 VO(acac)2, 环氧化试剂可以为叔丁基过氧化氢、 过氧化氢、 间氯过氧苯甲酸、 过氧苯 甲酸、过氧甲酸、过氧乙酸,反应溶剂可为二氯甲烷、 1,2-二氯乙烷、氯仿、 四氢呋喃、 苯、 甲苯等溶剂; 反应温度为 0"€〜室温, 反应时间为 1~48小 时。 In step d, a coordination reagent of metal vanadium is used as a catalyst, such as VO(acac) 2 , and the epoxidizing reagent may be t-butyl hydroperoxide, hydrogen peroxide, m-chloroperoxybenzoic acid, peroxybenzoic acid. , peroxyformic acid, peracetic acid, the reaction solvent can be dichloromethane, 1,2-dichloroethane, chloroform, tetrahydrofuran, benzene, toluene and other solvents; reaction temperature is 0" € ~ room temperature, reaction time is 1 ~ 48 hours.
在步骤 e中,在化合物 4的仲醇的保护试剂 RX中, R选自 BnOCH2-、 MeOCH2-、 t-Bu(Me)2Si -、 i-Pr3Si-和 t-BuPh2Si-; X为卤素, 例如 C1; 反 应中使用的碱可为三乙胺、 二异丙基乙胺、 DBU、 咪唑等; 反应溶剂可为 二氯甲垸、 1,2-二氯乙烷、 氯仿、 四氢呋喃、 苯、 甲苯、 二甲基甲酰胺; 反 应温度为 -10*C~45X。 In the step e, in the protective reagent RX of the secondary alcohol of the compound 4, R is selected from the group consisting of BnOCH 2 -, MeOCH 2 -, t-Bu(Me) 2 Si -, i-Pr 3 Si- and t-BuPh 2 Si - X is a halogen, such as C1; the base used in the reaction may be triethylamine, diisopropylethylamine, DBU, imidazole, etc.; the reaction solvent may be dichloromethane, 1,2-dichloroethane, Chloroform, tetrahydrofuran, benzene, toluene, dimethylformamide; The temperature should be -10*C~45X.
在步骤 f 中, 二烷基氯化铝试剂是例如二乙基氯化铝, N,N-二烷 锂由相应的二烷基胺经与丁基锂反应原位制得, 其中二烷基胺选自 N,N- 二异丙基胺、 N,N-二环己基胺和 2,2,6,6-四甲基六氢吡啶, 优选 2,2,6,6-四 甲基六氢吡啶; 反应温度为 -20"€~室温, 反应时间为 1~48小时。  In step f, the dialkyl aluminum chloride reagent is, for example, diethylaluminum chloride, and the N,N-dialkyllithium is prepared in situ from the corresponding dialkylamine by reaction with butyllithium, wherein the dialkyl group The amine is selected from the group consisting of N,N-diisopropylamine, N,N-dicyclohexylamine and 2,2,6,6-tetramethylhexahydropyridine, preferably 2,2,6,6-tetramethyl-6 Hydropyridine; reaction temperature is -20" € ~ room temperature, reaction time is 1 ~ 48 hours.
本领域技术人员可以理解, 在以上的合成中间体 II的方法中, 可以采 用步骤 c)至 e)中任何一步所得的反应产物作为原料直接进行随后的反应来 制备中间体 II。 例如, 可以采用式 (4)的化合物作为原料并进行如上所述的 步骤 d)至 f)来制备中间体 II, 或采用式 (5)的化合物作为原料并进行如上所 述的步骤 e)至 f)来制备中间体 II, 等等。  It will be understood by those skilled in the art that in the above method of synthesizing the intermediate II, the intermediate product can be prepared by directly carrying out the subsequent reaction using the reaction product obtained in any of the steps c) to e) as a raw material. For example, the compound of the formula (4) can be used as a raw material and the steps d) to f) as described above can be used to prepare the intermediate II, or the compound of the formula (5) can be used as a raw material and the step e) as described above can be carried out. f) to prepare intermediate II, and the like.
在另一个实施方案中, 提供了中间体 II的合成方法:
Figure imgf000009_0001
In another embodiment, a method of synthesizing Intermediate II is provided:
Figure imgf000009_0001
CH2〇R' CH 2 〇R'
II 其中  II where
R是羟基保护基, 选自: (i)烷基, (ii)芳烷基例如苄基, (iii)烷氧基亚 烷基, 例如烷氧基亚甲基, 如 MeOCH2-, (iv)芳烷氧基亚烷基, 例如芳烷 * ^亚甲基,如 BnOCH2-,或 (V)硅烷基,例如三苯基硅基、三异丙基硅基、 叔丁基二甲 基、 叔丁基二苯^ ^基; R is a hydroxy protecting group selected from the group consisting of: (i) an alkyl group, (ii) an aralkyl group such as a benzyl group, (iii) an alkoxyalkylene group such as an alkoxymethylene group such as MeOCH 2 -, (iv ) aralkyloxy alkylene, e.g. methylene aralkyl * ^, as BnOCH 2 -, or (V) silyl, such as triphenyl silicon, triisopropylsilyl, tert-butyldimethyl , tert-butyl diphenyl ^ ^ group;
R,是羟基保护基, 选自: (i)芳烷基例如三苯甲基, 或 (ii)硅烷基, 例如 三苯^ ^基、 三异丙 J¾基、 叔丁基二甲^ ^基、 叔丁^苯^ ^基; 该方法包括以下步骤:  R, is a hydroxy protecting group, selected from: (i) an aralkyl group such as a trityl group, or (ii) a silane group, such as a triphenyl group, a triisopropyl J3⁄4 group, a t-butyl dimethyl group , tert-butyl benzene ^ ^ base; the method comprises the following steps:
a) 中间体化合物 1经与异丙烯格氏试剂在卤化亚铜存在下反应得到化 合物 2
Figure imgf000010_0001
a) Intermediate compound 1 is reacted with an isopropenol Grignard reagent in the presence of a cuprous halide to obtain compound 2
Figure imgf000010_0001
其中 X为卤素或氰基,  Wherein X is a halogen or a cyano group,
b)将化合物 2的伯羟基选择性保护得化合物 3, b) selectively protecting the primary hydroxyl group of compound 2 to give compound 3,
Figure imgf000010_0002
Figure imgf000010_0002
其中 R,如上文所定义, X为卤素,  Where R, as defined above, X is a halogen,
c)将化合物 3在 Grubbs催化剂存在下, 经烯烃复分解反应得到环状 化合物 4, c) the compound 3 is subjected to olefin metathesis reaction in the presence of a Grubbs catalyst to obtain a cyclic compound 4,
Figure imgf000010_0003
Figure imgf000010_0003
其中 R,如上文所定义,  Where R, as defined above,
d) 将化合物 4 与环氧化试剂在金属钒试剂催化下立体选择性地得到 环氧化中间体 5,  d) stereoselectively obtaining an epoxidation intermediate 5 by catalyzing the compound 4 with an epoxidation reagent under a metal vanadium reagent,
Figure imgf000010_0004
Figure imgf000010_0004
e)将化合物 5的仲醇进行保护得到化合物 6,
Figure imgf000011_0001
e) protecting the secondary alcohol of compound 5 to give compound 6,
Figure imgf000011_0001
其中 X为卤素, R和 R,如上文所定义,  Wherein X is halogen, R and R, as defined above,
f)化合物 6在二烷基氯化铝试剂和 N,N-二烷基胺锂作用下环氧开环形 成中间体 II,  f) compound 6 is epoxy-opened to form intermediate II under the action of a dialkylaluminum chloride reagent and lithium N,N-dialkylamine,
Figure imgf000011_0002
Figure imgf000011_0002
其中 R和 R,如上文所定义。  Where R and R are as defined above.
在上述的反应中, 反应溶剂可以是极性或非极性的非质子溶剂, 优选 的溶剂包括但不限于四氢呋喃、 二氯甲烷、 氯仿、 二甲基甲酰胺、 二氧六 环、 乙醚。  In the above reaction, the reaction solvent may be a polar or non-polar aprotic solvent, and preferred solvents include, but are not limited to, tetrahydrofuran, dichloromethane, chloroform, dimethylformamide, dioxane, diethyl ether.
在步骤 a中, 反应溶剂可为四氢呋喃、 乙醚、 丁醚、 二氧六环。 优选 的溶剂可以是四氢呋喃。 反应时间为 1~48小时, 反应温度为 -78 〜室温。 卤化亚铜试剂可为 Cul、 CuBr或 CuBr.Me2S。 化合物 1可按文献 (Angew. Chem. Int. Ed. 2010, 49, 881)的方法制备。 In the step a, the reaction solvent may be tetrahydrofuran, diethyl ether, dibutyl ether or dioxane. A preferred solvent may be tetrahydrofuran. The reaction time is from 1 to 48 hours, and the reaction temperature is from -78 to room temperature. The cuprous halide reagent can be Cul, CuBr or CuBr.Me 2 S. Compound 1 can be produced according to the method of the literature (Angew. Chem. Int. Ed. 2010, 49, 881).
在步骤 b中, 伯羟基保护试剂 R,X选自三苯基氯化硅、 三异丙基氯化 硅、 叔丁基二甲基氯化硅、 叔丁基二苯基氯化硅、 三苯基氯甲烷。 反应溶 剂可为二甲基甲酰胺、 二氯甲烷、 氯仿、 甲苯。 碱包括有机碱如三乙胺、 In step b, the primary hydroxyl protecting agent R, X is selected from the group consisting of triphenylsilyl chloride, triisopropylsilyl chloride, tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride, three Phenylchloromethane. The reaction solvent may be dimethylformamide, dichloromethane, chloroform or toluene. The base includes an organic base such as triethylamine,
DBU、 咪唑、 二异丙基乙胺。 DBU, imidazole, diisopropylethylamine.
步骤 c、 d、 e、 f的反应条件如上文所述。  The reaction conditions of steps c, d, e, and f are as described above.
本领域技术人员可以理解, 在以上的合成中间体 II的方法中, 可以采 用步骤 a)至 e)中任何一步所得的反应产物作为原料直接进行随后的反应来 制备中间体 II。 例如, 可以采用式 (4)的化合物作为原料并进行如上所述的 步骤 d)至 f)来制备中间体 II, 或采用式 (2)的化合物作为原料并进行如上所 述的步骤 b)至 f)来制备中间体 II, 等等。 It will be understood by those skilled in the art that in the above process for the synthesis of intermediate II, the intermediate product can be prepared by directly carrying out the subsequent reaction using the reaction product obtained in any of steps a) to e) as a raw material. For example, a compound of the formula (4) can be used as a raw material and carried out as described above. The intermediates II are prepared by the steps d) to f), or the intermediates of the formula (2) are used as starting materials and the steps b) to f) as described above are carried out to prepare the intermediate II, and the like.
在另一方面, 本发明提供了下式 V的化合物:  In another aspect, the invention provides a compound of the formula V:
RO Ί RO Ί
R'O v  R'O v
其中  among them
R是氢或羟基保护基, 选自: (i)烷基, (ii)芳烷基例如苄基, (iii)烷氧 基亚烷基, 例如烷 亚甲基, 如 MeOCH2-, (iv)芳烷氧基亚烷基, 例如 芳烷氧基亚甲基, 如 BnOCH2-, 或 (V)硅烷基, 例如三苯 &、 三异丙基 硅基、 叔丁^ 甲 基、 叔丁^苯 基; R is a hydrogen or hydroxy protecting group selected from: (i) an alkyl group, (ii) an aralkyl group such as a benzyl group, (iii) an alkoxyalkylene group such as an alkylene group such as MeOCH 2 -, (iv An aralkoxyalkylene group, such as an aralkyloxymethylene group, such as a BnOCH 2 -, or a (V) silane group, such as triphenyl&, triisopropylsilyl, tert-butylmethyl, tert-butyl ^phenyl;
R,是羟基保护基, 选自: (i)芳烷基例如三苯甲基, 或 (ii)硅烷基, 例如 三苯^ ¾基、 三异丙^^基、 叔丁基二甲^ ¾基、 叔丁^苯^^基。  R, which is a hydroxy protecting group, is selected from the group consisting of: (i) an aralkyl group such as a trityl group, or (ii) a silane group such as a triphenyl group, a triisopropyl group, a tert-butyl group; Base, tert-butyl benzene ^ ^ base.
在优选的实施方案中, 所述式 V的化合物选自下列:  In a preferred embodiment, the compound of formula V is selected from the group consisting of:
Figure imgf000012_0001
Figure imgf000012_0001
另一方面, 本发明提供了制备式 V化合物的方法,
Figure imgf000013_0001
In another aspect, the invention provides a method of preparing a compound of formula V,
Figure imgf000013_0001
R是氢或羟基保护基, 选自: (i)烷基, (ii)芳烷基例如苄基, (iii)烷氧 基亚烷基, 例如烷氧基亚甲基, 如 MeOCH2-, (iv)芳烷氧基亚烷基, 例如 芳烷氧基亚甲基, 如 BnOCH2-, 或 (V)硅烷基, 例如三苯基硅基、 三异丙基 硅基、 叔丁^ 甲^^基、 叔丁^苯^^基; R is a hydrogen or hydroxy protecting group selected from the group consisting of: (i) an alkyl group, (ii) an aralkyl group such as a benzyl group, (iii) an alkoxyalkylene group such as an alkoxymethylene group such as MeOCH 2 -, (iv) an aralkoxyalkylene group, such as an aralkyloxymethylene group, such as a BnOCH 2 -, or a (V) silane group, such as a triphenylsilyl group, a triisopropylsilyl group, a tert-butyl group ^^基, 叔丁^苯^^基;
R,是羟基保护基, 选自: (i)芳烷基例如三苯甲基, 或 (ii)硅烷基, 例如 三苯 基、 三异丙 基、 叔丁基二甲 &、 叔丁 苯  R, which is a hydroxy protecting group, is selected from the group consisting of: (i) an aralkyl group such as a trityl group, or (ii) a silane group such as triphenyl, triisopropyl, tert-butyldimethyl, and tert-butylbenzene.
该方法包括以下步骤:  The method includes the following steps:
a) 中间体化合物 1经与异丙烯格氏试剂在卤化亚铜存在下反应得到化 合物 2  a) Intermediate compound 1 is reacted with isopropenol Grignard reagent in the presence of cuprous halide to obtain compound 2
Figure imgf000013_0002
Figure imgf000013_0002
其中 X为卤素或氛基,  Where X is a halogen or an aryl group,
b)将化合物 择性保护得化合 3,  b) selective compounding of the compound 3,
Figure imgf000013_0003
Figure imgf000013_0003
其中 R,如上文所定义, X为卤素,  Where R, as defined above, X is a halogen,
c)将化合物 3在 Grubbs催化剂存在下, 经烯烃复分解反应得到环状 化合物 4,
Figure imgf000014_0001
c) the compound 3 is subjected to olefin metathesis reaction in the presence of a Grubbs catalyst to obtain a cyclic compound 4,
Figure imgf000014_0001
其中 R,如上文所定义,  Where R, as defined above,
d) 将化合物 4 与环氧化试剂在金属钒试剂催化下立体选择性地得到 其中 R是氢的式 V  d) stereoselectively obtaining compound 4 with an epoxidizing reagent catalyzed by a metal vanadium reagent, wherein R is hydrogen
Figure imgf000014_0002
Figure imgf000014_0002
其中 R是氢, R,如上文所定义,  Wherein R is hydrogen, R, as defined above,
或者  Or
e)将其中 R是氢的式 V化合物的仲醇进行保护得到其中 R不是氢的 式 V化合物,  e) protecting a secondary alcohol of a compound of formula V wherein R is hydrogen to give a compound of formula V wherein R is not hydrogen,
Figure imgf000014_0003
Figure imgf000014_0003
其中 为¾素, R和 R,如上文所定义, 且 R不是氢。  Wherein is 3⁄4, R and R, as defined above, and R is not hydrogen.
在一个优选的实施方案中, 步骤 a)、 b)、 c)、 d)和 e)的反应条件如上 文所述。  In a preferred embodiment, the reaction conditions of steps a), b), c), d) and e) are as described above.
本领域技术人员可以理解, 在以上的合成化合物 V的方法中, 可以采 用步骤 a)至 d)中任何一步所得的反应产物作为原料直接进行随后的反应来 制备中间体 II。 例如, 可以采用式 (4)的化合物作为原料并进行如上所述的 步骤 d)至 e)来制备化合物 V,或采用式 (2)的化合物作为原料并进行如上所 述的步骤 b)至 e)来制备化合物 V,或采用式 (3)的化合物作为原料并进行如 上所述的步骤 c)至 e)来制备化合物 V, 等等。 在另一方面, 本发明提供了式 4的化合物: It will be understood by those skilled in the art that in the above process for synthesizing the compound V, the intermediate product can be prepared by directly carrying out the subsequent reaction using the reaction product obtained in any of the steps a) to d) as a raw material. For example, the compound of the formula (4) can be used as a raw material and the steps d) to e) as described above can be carried out to prepare the compound V, or the compound of the formula (2) can be used as a raw material and the steps b) to e as described above can be carried out. To prepare compound V, or to use compound of formula (3) as a starting material and to carry out steps c) to e) as described above to prepare compound V, and the like. In another aspect, the invention provides a compound of formula 4:
Figure imgf000015_0001
Figure imgf000015_0001
其中 R,是羟基保护基, 选自: (i)芳烷基例如三苯甲基, 或 (ii)硅烷基, 例如三苯 &、三异丙 基、叔丁 甲 &、叔丁基二苯^ ^基。  Wherein R is a hydroxy protecting group selected from the group consisting of: (i) an aralkyl group such as a trityl group, or (ii) a silane group such as triphenyl & triisopropyl, tert-butyl & tert-butyldiphenyl ^ ^ 基.
Figure imgf000015_0002
Figure imgf000015_0005
Figure imgf000015_0002
Figure imgf000015_0005
另一方面, 本发明提供了制备式 4化合物的方法,  In another aspect, the invention provides a method of preparing a compound of formula 4,
Figure imgf000015_0003
Figure imgf000015_0003
其中 R,是羟基保护基, 选自: (i)芳烷基例如三苯甲基, 或 (ii)硅烷基, 例如三苯^:基、三异丙 基、叔丁^!甲^:基、叔丁基二苯^ J¾基, 该方法包括以下步骤:  Wherein R is a hydroxy protecting group selected from the group consisting of: (i) an aralkyl group such as a trityl group, or (ii) a silane group such as a triphenyl group: a trisyl group, a triisopropyl group, a tert-butyl group! M ^: base, tert-butyl diphenyl ^ J3⁄4 base, the method comprises the following steps:
a) 中间体化合物 1经与异丙烯格氏试剂在卤化亚铜存在下反应得到化 合物 2  a) Intermediate compound 1 is reacted with isopropenol Grignard reagent in the presence of cuprous halide to obtain compound 2
Figure imgf000015_0004
Figure imgf000015_0004
其中 X为卤素或氛基,  Where X is a halogen or an aryl group,
b)将化合物 2的伯羟基选择性保护得化合物 3,
Figure imgf000016_0001
b) selectively protecting the primary hydroxyl group of compound 2 to give compound 3,
Figure imgf000016_0001
其中 R,如上文所定义, X为卤素,  Where R, as defined above, X is a halogen,
c)将化合物 3在 Grubbs催化剂存在下, 经烯烃复分解反应得到环状 化合物 4, c) the compound 3 is subjected to olefin metathesis reaction in the presence of a Grubbs catalyst to obtain a cyclic compound 4,
Figure imgf000016_0002
Figure imgf000016_0002
其中 R,如上文所定义。  Where R is as defined above.
在一个优选的实施方案中, 步骤 a)、 b)、 c)的反应条件如上文所述。 本领域技术人员可以理解, 在以上的合成化合物 4的方法中, 可以采 用步骤 a)至 b)中任何一步所得的反应产物作为原料直接进行随后的反应来 制备中间体 II。 例如, 可以采用式 (3)的化合物作为原料并进行如上所述的 步骤 c)来制备化合物 4, 或采用式 (2)的化合物作为原料并进行如上所述的 步骤 b)至 c)来制备化合物 4, 等等。  In a preferred embodiment, the reaction conditions of steps a), b), c) are as described above. It will be understood by those skilled in the art that in the above method of synthesizing the compound 4, the reaction product obtained in any of the steps a) to b) can be directly used as a starting material to carry out the subsequent reaction to prepare the intermediate II. For example, compound 4 can be prepared by using the compound of formula (3) as a starting material and carrying out step c) as described above, or using the compound of formula (2) as a starting material and carrying out steps b) to c) as described above. Compound 4, and so on.
在另一方面, 本发明提  In another aspect, the invention provides
Figure imgf000016_0003
Figure imgf000016_0003
其中 R,是氢或羟基保护基, 选自: (i)芳烷基例如三苯甲基, 或 (ii)硅烷 基, 例如三苯 JJ¾基、 三异丙 ^ ^基、 叔丁基二甲 JJ¾基、 叔丁基二苯基 娃基。  Wherein R is a hydrogen or hydroxy protecting group selected from: (i) an aralkyl group such as a trityl group, or (ii) a silane group such as a triphenyl JJ3⁄4 group, a triisopropyl group, a tert-butyl group JJ3⁄4 base, tert-butyldiphenyl group.
在优选的实施方案中, 所述式 III的化合物选自下列:
Figure imgf000017_0001
In a preferred embodiment, the compound of formula III is selected from the group consisting of:
Figure imgf000017_0001
另一方面, 本发明提供 法,  In another aspect, the invention provides a method,
Figure imgf000017_0002
Figure imgf000017_0002
其中 R,是氢或羟基保护基, 选自: (i)芳烷基例如三苯甲基, 或 (ii)硅烷 基, 例如三苯^^基、 三异丙^:基、 叔丁基二甲^ ¾基、 叔丁基二苯基 硅基,  Wherein R is a hydrogen or hydroxy protecting group selected from the group consisting of: (i) an aralkyl group such as a trityl group, or (ii) a silane group such as a triphenyl group, a triisopropyl group: a tert-butyl group M ^ 3⁄4 base, tert-butyl diphenyl silicon,
该方法包括以下步骤:  The method includes the following steps:
a) 中间体化合物 1经与异丙烯格氏试剂在卤化亚铜存在下反应得到其 中 R,是氢的式 III化合物  a) intermediate compound 1 is reacted with isopropenol Grignard reagent in the presence of cuprous halide to obtain a compound of formula III wherein R is hydrogen
Figure imgf000017_0003
Figure imgf000017_0003
其中 X为卤素或氰基,  Wherein X is a halogen or a cyano group,
或者  Or
b)将其中 R,是氢的式 III化合物的伯羟基选择性保护得到其中 R,不 是氢的式 III化合物,
Figure imgf000018_0001
b) selectively protecting a primary hydroxyl group of a compound of formula III wherein R is hydrogen, to give a compound of formula III wherein R is not hydrogen,
Figure imgf000018_0001
其中 R,如上文所定义, 且 R,不是氢, X为卤素。  Wherein R is as defined above, and R is not hydrogen and X is halogen.
在一个优选的实施方案中, 步骤 a)、 b)的反应条件如上文所述。  In a preferred embodiment, the reaction conditions of steps a), b) are as described above.
本领域技术人员可以理解, 在以上的合成式 III化合物的方法中, 可 以采用其中 R,是氢的式 III化合物作为原料并进行如上所述的步骤 b)来制 备其中 R,不是氢的式 III化合物。  It will be understood by those skilled in the art that in the above process for synthesizing a compound of formula III, a compound of formula III wherein R, which is hydrogen, can be employed as starting material and step b) as described above can be used to prepare formula III wherein R is not hydrogen. Compound.
在另一方面, 本发明提供了经过如上所述的中间体 II来合成式 I的恩 替卡韦的方法, 其特征在于利用该中间体 II与鸟嘌呤衍生物经 Mitsunobu 反应而得到恩替卡韦。  In another aspect, the invention provides a method of synthesizing entecavir of formula I via intermediate II as described above, characterized in that entecavir is obtained by the Mitsunobu reaction of the intermediate II with a guanine derivative.
在一个实施方案中, 式 I的恩替卡韦的合成方法包括以下步骤: c)将化合物 3在 Grubbs催化剂存在下, 经烯烃复分解反应得到环状 化合物 4, In one embodiment, the method for synthesizing entecavir of formula I comprises the steps of: c) subjecting compound 3 to the cyclic compound 4 via olefin metathesis in the presence of a Grubbs catalyst,
Figure imgf000018_0002
Figure imgf000018_0002
其中 R,如上文的式 II化合物所定义,  Wherein R is as defined by the compound of formula II above,
d) 将化合物 4 与环氧化试剂在金属钒试剂催化下立体选择性地得到 环氧化中间体 5, d) stereoselectively obtaining an epoxidation intermediate 5 by catalyzing the compound 4 with an epoxidation reagent under a metal vanadium reagent,
Figure imgf000018_0003
Figure imgf000018_0003
e)将化合物 5的仲醇进行保护得到化合物 6
Figure imgf000019_0001
e) protecting the secondary alcohol of compound 5 to give compound 6
Figure imgf000019_0001
其中 X为 素, R和 R,如上文的式 II化合物所定义,  Wherein X is a compound, R and R, as defined by the compound of formula II above,
f)化合物 6在二烷基氯化铝试剂和 N,N-二烷基胺锂作用下环氧开环形 成中间体 II,  f) compound 6 is epoxy-opened to form intermediate II under the action of a dialkylaluminum chloride reagent and lithium N,N-dialkylamine,
Figure imgf000019_0002
Figure imgf000019_0002
其中 R和 R,如上文的式 II化合物所定义,  Wherein R and R are as defined by the compound of formula II above,
g) 利用 Mitsunobu反应使中间体 II与 2- J^-6-氯 -鸟嘌呤偶联得到化 合物 8;  g) coupling intermediate II with 2-J^-6-chloro-guanine by Mitsunobu reaction to obtain compound 8;
Figure imgf000019_0003
Figure imgf000019_0003
h)化合物 8在酸性 frfr下水解得到式 I化合物  h) Compound 8 is hydrolyzed under acidic frfr to give a compound of formula I
Figure imgf000019_0004
在步骤 C中,反应溶剂可为二氯甲烷、 1,2-二氯乙烷、氯仿、四氢呋喃、 苯、 甲苯。 反应的催化剂可以为 Grubbs第一代或第二代催化剂, 用量为 0.1-20 eq%, 反应温度为室温〜 120 "€。
Figure imgf000019_0004
In the step C, the reaction solvent may be dichloromethane, 1,2-dichloroethane, chloroform, tetrahydrofuran, benzene or toluene. The catalyst for the reaction may be Grubbs first or second generation catalyst in an amount of from 0.1 to 20 eq%, and the reaction temperature is from room temperature to 120 "€.
在步骤 d中, 使用金属钒的配位试剂作为催化剂, 例如 VO(acac)2, 环氧化试剂可以为叔丁基过氧化氢、 过氧化氢、 间氯过氧苯甲酸、 过氧苯 甲酸、过氧甲酸、过氧乙酸,反应溶剂可为二氯甲烷、 1,2-二氯乙烷、氯仿、 四氢呋喃、 苯、 甲苯等溶剂; 反应温度为 0X〜室温, 反应时间为 1~48小 时。 In step d, a coordination reagent of metal vanadium is used as a catalyst, such as VO(acac) 2 , and the epoxidizing reagent may be t-butyl hydroperoxide, hydrogen peroxide, m-chloroperoxybenzoic acid, peroxybenzoic acid. , peroxyformic acid, peracetic acid, the reaction solvent can be dichloromethane, 1,2-dichloroethane, chloroform, tetrahydrofuran, benzene, toluene and other solvents; reaction temperature is 0X~ room temperature, reaction time is 1~48 hours .
在步骤 e中,在化合物 4的仲醇的保护试剂 RX中, R选自 BnOCH2-、 MeOCH2-、 t-Bu(Me)2Si -、 i-Pr3Si-和 t-BuPh2Si-; X为卤素, 例如 C1; 反 应中使用的碱可为三乙胺、 二异丙基乙胺、 DBU、 咪唑等; 反应溶剂可为 二氯甲烷、 1,2-二氯乙烷、 氯仿、 四氢呋喃、 苯、 甲苯、 二甲基甲酰胺; 反 应温度为 -10*C~45X。 In the step e, in the protective reagent RX of the secondary alcohol of the compound 4, R is selected from the group consisting of BnOCH 2 -, MeOCH 2 -, t-Bu(Me) 2 Si -, i-Pr 3 Si- and t-BuPh 2 Si - X is a halogen, such as C1; the base used in the reaction may be triethylamine, diisopropylethylamine, DBU, imidazole, etc.; the reaction solvent may be dichloromethane, 1,2-dichloroethane, chloroform , tetrahydrofuran, benzene, toluene, dimethylformamide; reaction temperature is -10*C~45X.
在步骤 f 中, 二烷基氯化铝试剂是例如二乙基氯化铝, N,N-二烷 锂由相应的二烷基胺经与丁基锂反应原位制得, 其中二烷基胺选自 N,N- 二异丙基胺、 N,N-二环己基胺和 2,2,6,6-四甲基六氢吡啶, 优选 2,2,6,6-四 甲基六氢吡啶; 反应温度为 -20"€~室温, 反应时间为 1~48小时。  In step f, the dialkyl aluminum chloride reagent is, for example, diethylaluminum chloride, and the N,N-dialkyllithium is prepared in situ from the corresponding dialkylamine by reaction with butyllithium, wherein the dialkyl group The amine is selected from the group consisting of N,N-diisopropylamine, N,N-dicyclohexylamine and 2,2,6,6-tetramethylhexahydropyridine, preferably 2,2,6,6-tetramethyl-6 Hydropyridine; reaction temperature is -20" € ~ room temperature, reaction time is 1 ~ 48 hours.
在步骤 g中, Mitsunobu反应试剂为膦催化剂如三苯基磷和偶氮二甲 酸二乙酯或偶氮二甲酸二异丙酯, 反应溶剂可为非质子溶剂, 例如四氢呋 喃、 二氯甲烷、 二氧六环、 乙醚、 甲苯等; 优选四氢呋喃。 反应温度为 -23 "C〜室温。 反应时间为 1~48小时。  In step g, the Mitsunobu reaction reagent is a phosphine catalyst such as triphenylphosphine and diethyl azodicarboxylate or diisopropyl azodicarboxylate, and the reaction solvent may be an aprotic solvent such as tetrahydrofuran, dichloromethane, or Oxycyclohexane, diethyl ether, toluene, etc.; tetrahydrofuran is preferred. The reaction temperature is -23 "C~ room temperature. The reaction time is 1 to 48 hours.
在步骤 h中, 反应溶剂为非质子或质子溶剂, 例如四氢呋喃、 二氧六 环、 甲醇、 乙醇等, 所用的酸为无机酸例如盐酸、 硫酸等。 反应温度为室 温〜 120"€。 反应时间为 3~48小时。  In the step h, the reaction solvent is an aprotic or protic solvent such as tetrahydrofuran, dioxane, methanol, ethanol or the like, and the acid used is a mineral acid such as hydrochloric acid, sulfuric acid or the like. The reaction temperature is room temperature ~ 120" €. The reaction time is 3 to 48 hours.
本领域技术人员可以理解, 在以上合成恩替卡韦的方法中, 可以采用 步骤 c)至 g)中任何一步所得的反应产物作为原料直接进行随后的反应来制 备式 (I)的恩替卡韦。 例如, 可以采用式 (4)的化合物作为原料并进行如上所 述的步骤 d)至 h)来制备式 (I)的恩替卡韦,或采用式 (5)的化合物作为原料并 进行如上所述的步骤 e)至 h)来制备式 (I)的恩替卡韦, 等等。 It will be understood by those skilled in the art that in the above process for synthesizing entecavir, the reaction product obtained in any of the steps c) to g ) can be directly used as a raw material to carry out the subsequent reaction to prepare entecavir of the formula (I). For example, a compound of the formula (4) can be used as a raw material and carried out as described above. Steps d) to h) to prepare entecavir of formula (I), or to use the compound of formula (5) as a starting material and to carry out steps e) to h) as described above to prepare entecavir of formula (I), etc. .
在另一个实施方案中, 式 I的恩替卡韦的合成方法包括以下步骤: a) 中间体化合物 1经与异丙烯格氏试剂在卤化亚铜存在下反应得到化 合物 2  In another embodiment, the method of synthesizing entecavir of Formula I comprises the steps of: a) intermediate compound 1 being reacted with an isopropenol Grignard reagent in the presence of a cuprous halide to provide a compound 2
Figure imgf000021_0001
Figure imgf000021_0001
其中 X为卤素或氛基,  Where X is a halogen or an aryl group,
b)将化合物 择性保护得化合 3,
Figure imgf000021_0002
b) compounding the compounds to the compound 3,
Figure imgf000021_0002
其中 R,如上文所定义, X为卤素,  Where R, as defined above, X is a halogen,
c)将化合物 3在 Grubbs催化剂存在下, 经烯烃复分解反应得到环状 化合物 4,
Figure imgf000021_0003
c) the compound 3 is subjected to olefin metathesis reaction in the presence of a Grubbs catalyst to obtain a cyclic compound 4,
Figure imgf000021_0003
其中 R,如上文所定义,  Where R, as defined above,
d) 将化合物 4 与环氧化试剂在金属钒试剂催化下立体选择性地得到 环氧化中间体 5,
Figure imgf000021_0004
e)将化合物 5的
d) stereoselectively obtaining epoxidation intermediate 5 with compound 4 and an epoxidation reagent catalyzed by a metal vanadium reagent,
Figure imgf000021_0004
e) Compound 5
Figure imgf000022_0001
Figure imgf000022_0001
其中 X为卤素, R和 R,如上文所定义,  Wherein X is halogen, R and R, as defined above,
f)化合物 6在二烷基氯化铝试剂和 N,N-二烷基胺锂作用下环氧开环形 成中间体 II, f) compound 6 is epoxy-opened to form intermediate II under the action of a dialkylaluminum chloride reagent and lithium N,N-dialkylamine,
Figure imgf000022_0002
Figure imgf000022_0002
其中 R和 R,如上文所定义,  Where R and R are as defined above,
g) 利用 Mitsunobu反应使中间体 II与 2- J^-6-氯 -鸟嘌呤偶联得到化 合物 8;
Figure imgf000022_0003
g) coupling intermediate II with 2-J^-6-chloro-guanine using Mitsunobu reaction to give compound 8;
Figure imgf000022_0003
h)化合物 8在酸性条件下水解得到式 I化合物
Figure imgf000023_0001
h) Compound 8 is hydrolyzed under acidic conditions to give a compound of formula I
Figure imgf000023_0001
在上述的反应中, 反应溶剂为极性或非极性溶剂, 优选的溶剂是四氢 呋喃、 二氯甲烷、 氯仿、 甲醇、 乙醇、 二甲基甲酰胺、 二氧六环、 乙醚。  In the above reaction, the reaction solvent is a polar or non-polar solvent, and preferred solvents are tetrahydrofuran, dichloromethane, chloroform, methanol, ethanol, dimethylformamide, dioxane, diethyl ether.
在步骤 a中, 反应溶剂可为四氢呋喃、 乙醚、 丁醚、 二氧六环。 优选 的溶剂可以是四氢呋喃。 反应时间为 1~48小时, 反应温度为 -78 〜室温。 卤化亚铜试剂可为 Cul、 CuBr或 CuBr.Me2S。 化合物 1可按文献 (Angew. Chem. Int. Ed. 2010, 49, 881)的方法制备。 In the step a, the reaction solvent may be tetrahydrofuran, diethyl ether, dibutyl ether or dioxane. A preferred solvent may be tetrahydrofuran. The reaction time is from 1 to 48 hours, and the reaction temperature is from -78 to room temperature. The cuprous halide reagent can be Cul, CuBr or CuBr.Me 2 S. Compound 1 can be produced according to the method of the literature (Angew. Chem. Int. Ed. 2010, 49, 881).
在步骤 b中, 伯羟基保护试剂 R,X选自三苯基氯化硅、 三异丙基氯化 硅、 叔丁基二甲基氯化硅、 叔丁基二苯基氯化硅、 三苯基氯甲烷。 反应溶 剂可为二甲基甲酰胺、 二氯甲烷、 氯仿、 甲苯。 碱包括有机碱如三乙胺、 In step b, the primary hydroxyl protecting agent R, X is selected from the group consisting of triphenylsilyl chloride, triisopropylsilyl chloride, tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride, three Phenylchloromethane. The reaction solvent may be dimethylformamide, dichloromethane, chloroform or toluene. The base includes an organic base such as triethylamine,
DBU、 咪唑、 二异丙基乙胺。 DBU, imidazole, diisopropylethylamine.
步骤 c、 d、 e、 f、 g、 h的反应条件如上文所述。  The reaction conditions of the steps c, d, e, f, g, h are as described above.
在更优选的实施方案中, 恩替卡韦的合成路线如下所示, In a more preferred embodiment, the synthetic route of entecavir is as follows,
b; b;
Figure imgf000024_0001
Figure imgf000024_0001
其中, 步骤 a)到 h)的反应条件和基团定义如上文所述, 化合物 1可按 (Angew. Chem. Int. Ed. 2010, 49, 881)的方法制备。 Wherein the reaction conditions and group definitions of steps a) to h) are as described above, and Compound 1 can be produced by the method of (Angew. Chem. Int. Ed. 2010, 49, 881).
在特别优选的实施方案中, 恩替卡韦的合成路线如下所示, In a particularly preferred embodiment, the synthetic route of entecavir is as follows,
粉末形式 Powder form
Br  Br
b; b;
Figure imgf000025_0001
Figure imgf000025_0001
其中步骤 a)到 h)的反应条件和基团定义如上文所述, 化合物 1按照 Angew. Chem. Int. Ed. 2010, 49, 881的方法制备, 第一步反应为粉末形式。  Wherein the reaction conditions and group definitions of steps a) to h) are as described above, compound 1 is prepared according to the method of Angew. Chem. Int. Ed. 2010, 49, 881, and the first step is in powder form.
本领域技术人员可以理解, 在以上合成恩替卡韦的方法中, 可以采用 步骤 a)至 g)中任何一步所得的反应产物作为原料直接进行随后的反应来制 备式 (I)的恩替卡韦。 例如, 可以采用式 (4)的化合物作为原料并进行如上所 述的步骤 d)至 h)来制备式 (I)的恩替卡韦,或采用式 (2)的化合物作为原料并 进行如上所述的步骤 b)至 h)来制备式 (I)的恩替卡韦, 等等。 具体实施方式 It will be understood by those skilled in the art that in the above process for synthesizing entecavir, the reaction product obtained in any of steps a) to g ) can be used as a raw material to directly carry out the subsequent reaction to prepare entecavir of the formula (I). For example, the compound of the formula (4) can be used as a raw material and the steps d) to h) as described above can be carried out to prepare entecavir of the formula (I), or the compound of the formula (2) can be used as a raw material and the steps as described above can be carried out. b) to h) to prepare entecavir of formula (I), and the like. Detailed ways
通过以下实施例对本发明的方法进行进一步的说明。 应当理解, 提供 以下实施例的目的仅仅是为了能够更好的理解本发明, 而不是以任何方式 限定本发明的范围。 The method of the present invention is further illustrated by the following examples. It is to be understood that the following examples are provided only for a better understanding of the invention, and not in any way. The scope of the invention is defined.
在本申请中使用的缩写具有如下含义,  The abbreviations used in this application have the following meanings,
缩写:  Abbreviation:
Boc 叔丁  Boc Tert
DEAD 偶氮二甲酸二乙酯  DEAD diethyl azodicarboxylate
DIPEA 二异丙基乙胺  DIPEA diisopropylethylamine
EtOAc 乙酸乙酯  EtOAc ethyl acetate
MOMC1 甲 甲基氯化物  MOMC1 methyl chloride
MOMO 甲 甲氧基  MOMO methyl methoxy
TBAF 四丁基氟化铵  TBAF tetrabutylammonium fluoride
THF 四氢呋喃  THF tetrahydrofuran
t-Bu(Me)2Si 叔丁^ ^甲^ ^基 t-Bu(Me) 2 Si tert-butyl ^ ^甲 ^ ^ base
TBS 叔丁基二甲^:基  TBS tert-butyl dimethyl group: base
TBSC1 叔丁基二甲基氯硅烷 实 醇 (化合物 2)  TBSC1 tert-butyldimethylsilyl chloride solid alcohol (compound 2)
Figure imgf000026_0001
Figure imgf000026_0001
Fw 1 14 145/191 156  Fw 1 14 145/191 156
Wt 1 .6 100ml/1 .0  Wt 1 .6 100ml/1 .0
mmol 14.2 50/5.0  Mmmol 14.2 50/5.0
将 l.Og Cul (5mmol)悬浮于 50ml无水乙醚中, 冷至 -20*C , 在氩气保 护下滴加异丙烯格氏试剂 0.5M的 100ml THF溶液 (50mmol),加毕 -20*€搅 拌 25min, 冷至 -78"€, 滴加含有 1.6g (14.2mmol)化合物 1的 15ml THF溶 液, 加毕升温至 -20"€搅拌反应 16小时, 然后加饱和 NH4C1 200ml, 分出 有机层, 水层再用 EtOAc 100ml X 2萃取, 合并有机层, 水洗, 蒸干得油 状物 2.63g。将上述油状物加 20ml THF、 30ml H20,搅拌下加 3.0g NaI04, 室温搅拌 3h。加饱和 Na2S03, 分出有机层, 水层用 EtOAc 20ml X 2萃取, 合并萃取液, 饱和 NaCl洗涤, 洗后以无水 Na2S04干燥, 过滤, 滤液蒸干 得产物 1.83g (收率 83%)。 The l.Og Cul (5 mmol) was suspended in 50 ml of anhydrous diethyl ether, cooled to -20*C, and a solution of isopropene Grignard reagent 0.5 M in 100 ml of THF (50 mmol) was added dropwise under argon atmosphere. Stir for 25 min, cool to -78" €, add a solution of 1.6 g (14.2 mmol) of compound 1 in 15 ml of THF, add the temperature to -20", stir the reaction for 16 hours, then add saturated NH 4 C1 200 ml, separate The organic layer was extracted with EtOAc EtOAc (EtOAc)EtOAc. 2.63 g. 20 ml of THF and 30 ml of H 2 0 were added to the above oil, and 3.0 g of NaI0 4 was added under stirring, and the mixture was stirred at room temperature for 3 h. Saturated Na 2 S0 3, the organic layer was separated, the aqueous layer was washed with saturated EtOAc 20ml X 2 extraction with NaCl extracts were combined, washed dried over anhydrous Na 2 S0 4, filtered and the filtrate evaporated to dryness to give 1.83 g of the product ( Yield 83%).
[a]D 20 = -4.9 (c 1.1, CHC13); [a] D 20 = -4.9 (c 1.1, CHC1 3 );
JH匪 R (300M, CDC13, ppm) δ 5.82 (m, 1H), 5.21 (s, 1H), 5.16 (d, 1H, J=9.3Hz), 4.92 (s, 1H), 4.82(s, 1H), 3.92-3.81 (m, 2H), 3.71 (dd, 1H, J=ll.l, 5.4Hz), 2.39 (m, 1H), 2.29-2.27 (m, 1H), 2.09 (m, 1H), 1.73 (s, 3H); J H匪R (300M, CDC1 3 , ppm) δ 5.82 (m, 1H), 5.21 (s, 1H), 5.16 (d, 1H, J=9.3Hz), 4.92 (s, 1H), 4.82(s, 1H), 3.92-3.81 (m, 2H), 3.71 (dd, 1H, J=ll.l, 5.4Hz), 2.39 (m, 1H), 2.29-2.27 (m, 1H), 2.09 (m, 1H) , 1.73 (s, 3H);
13C NMR (100M, CDCI3, ppm ) δ 143.4, 134.4, 118.8, 113.7, 73.0, 65.0, 54.0, 40.2, 21.6 实施例 2: 制备 (3R,4S)-3- ((叔丁基二甲基硅氧基)甲基) -2-甲基庚 -1,6- 二烯 _4- (化合物 3, 其中 R,=t-Bu(Me)2Si-) 13 C NMR (100M, CDCI3, ppm) δ 143.4, 134.4, 118.8, 113.7, 73.0, 65.0, 54.0, 40.2, 21.6 Example 2: Preparation of (3R,4S)-3- ((tert-butyldimethylsilyl) Oxy)methyl)-2-methylhepta-1,6-diene_4- (Compound 3, wherein R,=t-Bu(Me) 2 Si-)
Figure imgf000027_0001
S
Figure imgf000027_0001
S
Fw 156 150/68  Fw 156 150/68
Wt(mg) 232 245/202  Wt(mg) 232 245/202
m mol 1 .48 1 .63/2.97  m mol 1 .48 1 .63/2.97
mol/mol 1 1 .1 /2  Mol/mol 1 1 .1 /2
将 232mg的 2加 7.5ml CH2Cl2 il 加入 202mg咪峻, 冷至 0*C , 搅拌下加入 245mg TBSCl, 加毕 0"C到室温 10小时。 加入 10ml水, 分出 有机层, 水洗, 无水 Na2S04干燥, 过滤, 经硅胶短柱纯化,石油醚 /EtOAc (50/1)洗脱, 得到产物 290mg(72.3%), Rf=0.75 (石油醚 /EtOAc(20/l))。 Add 232 mg of 2 plus 7.5 ml of CH 2 Cl 2 il to 202 mg of Mi Jun, cool to 0*C, add 245 mg of TBSCl with stirring, add 0"C to room temperature for 10 hours. Add 10 ml of water, separate the organic layer, and wash with water. dried over anhydrous Na 2 S0 4, filtered and purified by a short column of silica gel, petroleum ether / EtOAc (50/1) to give the product 290mg (72.3%), Rf = 0.75 ( petroleum ether / EtOAc (20 / l)) .
[a]D 20 = -25 (c 0.5, CHC13); [a] D 20 = -25 (c 0.5, CHC1 3 );
JH NMR (300M, CDC13, ppm) δ 5.98-5.86 (m, 1H), 5.12 (d, 1H, J=6.3Hz), 5.07 (s, 1H), 4.86 (s, 1H), 4.76 (s, IH), 3.94-3.77 (m, 3H), 2.09-2.35 (m, 3H), 1.71 (s, 3H), 0.90 (s, 9H), 0.08 (s, 6H); 13C NMR (100M, CDCI3, ppm ) δ 143.6, 135.5, 116.9, 113.4, 74.0, 66.9, 53.3, 39.8, 25.8, 22.0, 18.1。 J H NMR (300M, CDC1 3 , ppm) δ 5.98-5.86 (m, 1H), 5.12 (d, 1H, J=6.3Hz), 5.07 (s, 1H), 4.86 (s, 1H), 4.76 (s , IH), 3.94-3.77 (m, 3H), 2.09-2.35 (m, 3H), 1.71 (s, 3H), 0.90 (s, 9H), 0.08 (s, 6H); 13 C NMR (100M, CDCI3, ppm) δ 143.6, 135.5, 116.9, 113.4, 74.0, 66.9, 53.3, 39.8, 25.8, 22.0, 18.1.
HR-MS (ESI)计算值 C15H3102Si (M+H)+ 271.2088, 实测值 271.2087 实施例 3: 制备 (lS,2R)-2- ((叔丁基二甲 J¾氧基)甲基) -3-甲基环戊 -3- 烯 -1-醇 ( ,=t-Bu(Me)2Si-) HR-MS (ESI) calcd for C 15 H 31 0 2 Si ( M + H) + 271.2088, found 271.2087 Example 3: Preparation of (lS, 2R) -2- ((tert-butyl-dimethoxy J¾ group) Methyl)-3-methylcyclopent-3-en-1-ol ( ,=t-Bu(Me) 2 Si-)
SS
Figure imgf000028_0001
Figure imgf000028_0001
Fw 270 848  Fw 270 848
Wt(mg) 820 50  Wt(mg) 820 50
m mol 3 2% X3  m mol 3 2% X3
820mg化合物 3,溶于 20ml二氯甲烷,在氩气氛中加入 50mg Grubbs 二代催化剂 (2%), 于氩气氛中加热回流搅拌 2小时, 减压浓缩, 残留物硅 胶短柱纯化,石油醚 /EtOAc (20/1)洗脱,得到产物 600mg (81.5%), Rf=0.35 (石油醚 /EtOAc(10/l))。  820 mg of compound 3, dissolved in 20 ml of dichloromethane, 50 mg of Grubbs second-generation catalyst (2%) was added in an argon atmosphere, and the mixture was stirred under reflux for 2 hours under argon atmosphere, and concentrated under reduced pressure. Elution with EtOAc (20/1) gave EtOAc (EtOAc:EtOAc)
[a]D 20 = +34 (c 0.25, CHC13); [a] D 20 = +34 (c 0.25, CHC1 3 );
!H NMR (300M, CDC13, ppm) δ 5.32 (s, 1H), 4.34-4.29 (m, 1H), 3.85 (dd, 1H, J= 9.9, 4.8Hz) 3.46 (t, J= 8.4Hz), 2.64-2.56 (m, 2H), 2.21-2.16 (m, 1H), 1.66 (s, 3H), 0.9 (s, 9H), 0.10 (s, 6H). ! H NMR (300M, CDC1 3 , ppm) δ 5.32 (s, 1H), 4.34-4.29 (m, 1H), 3.85 (dd, 1H, J = 9.9, 4.8Hz) 3.46 (t, J = 8.4Hz) , 2.64-2.56 (m, 2H), 2.21-2.16 (m, 1H), 1.66 (s, 3H), 0.9 (s, 9H), 0.10 (s, 6H).
13C NMR (125M, CDC13, ppm ) δ 138.1, 123.4, 64.1, 59.2, 39.9, 25.9, 13 C NMR (125M, CDC1 3 , ppm ) δ 138.1, 123.4, 64.1, 59.2, 39.9, 25.9,
18.2, 15.3, -5.5, -5.5. 18.2, 15.3, -5.5, -5.5.
HR-MS (ESI)计算值 C13H2702Si (M+H)+ : 243.1775,实测值 243.1772 实施例 4:制备 (lS,2R,3S,5R)-2- ((叔丁基二甲^^氧基)甲基) -1-甲基 -6- 氧杂 -二环 [3.1.0】己 -3-醇 (化合物 5, 其中 R,=t-Bu(Me)2Si-)
Figure imgf000029_0001
HR-MS (ESI) calcd for C 13 H 27 0 2 Si ( M + H) +: 243.1775, found 243.1772 Example 4: Preparation of (lS, 2R, 3S, 5R ) -2- (( tert- Methoxycarbonyl)methyl-1-methyl-6-oxa-bicyclo[3.1.0]hexan-3-ol (Compound 5, wherein R,=t-Bu(Me) 2 Si-)
Figure imgf000029_0001
Fw 242 90/265  Fw 242 90/265
Wt(mg) 700 0.83ml/56  Wt(mg) 700 0.83ml/56
m mol 2.89 6/cat  m mol 2.89 6/cat
700mg (2.89mmol)化合物 4加 15ml 1,2-二氯乙烷溶解, 加入 50mg VO(acac)2, 水盐冷却至 -5*C , 滴加含 0.83ml 70%的 t-BuOOH的 1,2-二氯 乙烷 5ml, 加毕在 -5 至室温搅拌反应 5小时, TLC显示原料斑点消失, 将反应液冷至 0"€, 加饱和 Na2SO310ml, 搅拌 30分钟, 分出有机层, 水 洗, 无水 Na2S04干燥, 过滤, 滤液经硅胶短柱纯化, 石油醚 /EtOAc(10/l) 洗脱, 得产物 703mg (94%)。 700 mg (2.89 mmol) of compound 4 was dissolved in 15 ml of 1,2-dichloroethane, 50 mg of VO(acac) 2 was added , the water salt was cooled to -5*C, and 0.83 of 70% of t-BuOOH was added dropwise. 5 ml of 2-dichloroethane, stirred for 5 hours at -5 to room temperature, TLC showed disappearance of the starting material spots, the reaction solution was cooled to 0" €, saturated Na 2 SO 3 10 ml was added, stirred for 30 minutes, and organic layer, washed with water, dried over anhydrous Na 2 S0 4, filtered, and the filtrate was purified by a short column of silica gel, eluting with petroleum ether / EtOAc (10 / l), to give the product 703mg (94%).
[a]D 20 = +25.6 (c 0.285, CHC13); [a] D 20 = +25.6 (c 0.285, CHC1 3 );
JH匪 R (300M, CDC13, ppm) δ 3.92 (d, 1H, J=6.3Hz), 3.75-3.63 (m, 2H), 3.43 (s, 1H), 2.19-2.09 (m, 2H), 1.99-1.94 (m, 1H), 1.48 (s, 3H), 0.87 (s, 9H), 0.04 (s, 6H); J H匪R (300M, CDC1 3 , ppm) δ 3.92 (d, 1H, J=6.3Hz), 3.75-3.63 (m, 2H), 3.43 (s, 1H), 2.19-2.09 (m, 2H), 1.99-1.94 (m, 1H), 1.48 (s, 3H), 0.87 (s, 9H), 0.04 (s, 6H);
13C NMR (125M, CDC13, ppm ) δ 75.1, 66.5, 64.8, 62.3, 54.7, 38.4, 25.8, 18.1, 15.5, -5.6, -5.8. 13 C NMR (125M, CDC1 3 , ppm ) δ 75.1, 66.5, 64.8, 62.3, 54.7, 38.4, 25.8, 18.1, 15.5, -5.6, -5.8.
HR-MS (ESI)计算值 C13H2703Si (M+H)+ : 259.1724,实测值 259.1717 实施例 5:制备 (lS,2R,3S,5R)-3- (叔丁 甲 <S^|LS -2- ((叔丁基二甲 基硅氧基)甲基) -1-甲基 -6-氧杂 -二环 [3.1.0】己烷(化合物 6, 其中 R=R'=t-Bu(Me)2Si-)
Figure imgf000030_0001
HR-MS (ESI) calcd for C 13 H 27 0 3 Si ( M + H) +: 259.1724, found 259.1717 Example 5: Preparation of (lS, 2R, 3S, 5R ) -3- ( tert-A <S ^|LS -2-((tert-Butyldimethylsilyloxy)methyl)-1-methyl-6-oxa-bicyclo[3.1.0]hexane (Compound 6, wherein R=R' =t-Bu(Me) 2 Si-)
Figure imgf000030_0001
Fw 258 150/68 Fw 258 150/68
Wt(mg) 700 749/430  Wt(mg) 700 749/430
mmol 2.7 4.9/6.2  Mmmol 2.7 4.9/6.2
700mg (2.7mmol)化合物 5溶于 8ml DMF,依次加入 749mg TBSC1和 430mg咪唑, 加毕, 室温搅拌 4小时, 加 50ml石油醚稀释, 水洗, 无水 Na2S04干燥, 过滤, 滤液经硅胶短柱纯化, 石油醚 /EtOAc(60/l)洗脱, 得 到产物 835mg (83%), Rf= 0·55(石油醚 /乙醚 =20/1)。 700 mg (2.7 mmol) of compound 5 was dissolved in 8 ml of DMF, and 749 mg of TBSC1 and 430 mg of imidazole were added in sequence. After the addition, the mixture was stirred at room temperature for 4 hours, diluted with 50 ml of petroleum ether, washed with water, dried over anhydrous Na 2 SO 4 , filtered and filtered. Column purification, elution with petroleum ether /EtOAc (EtOAc /EtOAc) (EtOAc)
[a]D 20 = +35 (c 0.15, CHC13); [a] D 20 = +35 (c 0.15, CHC1 3 );
JH匪 R (300M, CDC13, ppm) δ 4.27 (d, 1H, J=7.5Hz), 3.68 (d, 2H, J=3.3Hz), 3.26 (s,lH), 2.14-2.07 (m,lH), 2.03 (s, 1H), 1.86-1.81 (m, 1H), 1.41 (s, 3H), 0.88 (s, 9H), 0.87 (s, 9H), 0.05 (s, 6H), 0.03 (s, 6H); J H匪R (300M, CDC1 3 , ppm) δ 4.27 (d, 1H, J=7.5Hz), 3.68 (d, 2H, J=3.3Hz), 3.26 (s,lH), 2.14-2.07 (m, lH), 2.03 (s, 1H), 1.86-1.81 (m, 1H), 1.41 (s, 3H), 0.88 (s, 9H), 0.87 (s, 9H), 0.05 (s, 6H), 0.03 (s , 6H);
13C匪 R (125M, CDCI3, ppm ) δ 76.4, 66.1, 64.9, 62.6, 55.3, 39.0, 26.0, 25.8, 18.2, 18.1, 16.0, -5.7,-5.7, -4.5, -4.5; 13 C匪R (125M, CDCI3, ppm ) δ 76.4, 66.1, 64.9, 62.6, 55.3, 39.0, 26.0, 25.8, 18.2, 18.1, 16.0, -5.7, -5.7, -4.5, -4.5;
HR-MS (ESI)计算值 C19H4103Si2 (M+H)+: 373.2589,实测值 373.2592 实施例 6:制备叔丁基(((18,211,38,511)-3-(甲氧基甲氧基)-1-甲基-6-氧杂 -二环 [3·1·0】己 -2-基)甲氧基)二甲基硅烷 (化合物 6, 其中 R=CH3OCH2-, R'=t-B HR-MS (ESI) calcd for C 19 H 41 0 3 Si 2 (M + H) +: 373.2589, Found 373.2592 Example 6: Preparation of tert-butyl (((18,211,38,511) -3- (methoxymethoxy)-1-methyl-6-oxa-bicyclo[3·1·0]hex-2-yl)methoxy)dimethylsilane (Compound 6, wherein R=CH 3 OCH 2 -, R'=tB
Figure imgf000030_0002
Figure imgf000030_0002
Fw 258 80/129  Fw 258 80/129
Wt(mg) 370 0.94ml/2.16ml  Wt(mg) 370 0.94ml/2.16ml
mmol 1 .55 12.4/12.4  Mmmol 1 .55 12.4/12.4
将 370mg (1.55mmol)化合物 5溶于 15ml CH2C12,加入 2.16ml DIPEA (12.2mmol), 水浴冷却后滴加 0.94ml MOMCl, 加毕 0"C至室温搅摔过夜, 减压蒸除溶剂, 残留物加 EtOAc稀释, 水洗, 无水 Na2S04干燥, 过滤, 滤液经硅胶短柱纯化, 石油醚 /EtOAc (30/l)洗脱, 得产物 390mg (90.1%), Rf=0.45 (石油醚 /乙醚 =6/1)。 370 mg (1.55 mmol) of compound 5 was dissolved in 15 ml of CH 2 C1 2 and 2.16 ml of DIPEA was added. (12.2 mmol), cooled with water dropwise 0.94ml MOMCl, plus complete 0 "C to room temperature and stir overnight fall, the solvent was distilled off under reduced pressure, the residue was diluted with EtOAc, washed with water, dried over anhydrous Na 2 S0 4, filtered and the filtrate Purification by silica gel EtOAc (EtOAc/EtOAc)
[a]D 20 = +33.1 (c 0.175, CHC13); [a] D 20 = +33.1 (c 0.175, CHC1 3 );
JH匪 R (300M, CDC13, ppm) δ 4.59 (s, 2H), 4.12 (d, 1H, J=7.2Hz), 3.70 (m, 2H), 3.33 (s, 4H), 2.20 (m, 1H), 2.11-2.00 (m, 2H), 1.44 (s, 3H), 0.88 (s, 9H), 0.05 (s, 6H); J H匪R (300M, CDC1 3 , ppm) δ 4.59 (s, 2H), 4.12 (d, 1H, J=7.2Hz), 3.70 (m, 2H), 3.33 (s, 4H), 2.20 (m, 1H), 2.11-2.00 (m, 2H), 1.44 (s, 3H), 0.88 (s, 9H), 0.05 (s, 6H);
13C NMR (125M, CDC13, ppm) δ 95.3, 80.4, 65.7, 36.0, 25.8, 18.0, 15.7, -5.6, -5.8; 13 C NMR (125M, CDC1 3 , ppm) δ 95.3, 80.4, 65.7, 36.0, 25.8, 18.0, 15.7, -5.6, -5.8;
HR-MS (ESI) 计算值 C15H3()04SiNa (M+Na)+: 325.18110; 实测值 325.18037. 实施例 7:制备 (lR,3R,4S)-3- ((叔丁基二甲^ *J^)甲基) -4- (甲氧基甲 ¾J - -亚甲基-环戊醇 (化合物 II, 其中 R=CH3OCH2-, R'=t-Bu(Me)2Si-) HR-MS (ESI) calcd for C 15 H 3 () 0 4 SiNa (M + Na) +:. 325.18110; found 325.18037 Example 7: Preparation of (lR, 3R, 4S) -3- (( tert-butyl Dimethyl^*J^)methyl)-4-(methoxymethyl3⁄4J-methylene-cyclopentanol (Compound II, where R=CH 3 OCH 2 -, R'=t-Bu(Me) 2 Si-)
Figure imgf000031_0001
Figure imgf000031_0001
Fw 302 141/2.5M/0.9M  Fw 302 141/2.5M/0.9M
wt(mg) 70 131 /0.37ml/1 m l  Wt(mg) 70 131 /0.37ml/1 m l
mmol 0.232 0.927/0.927/0.927  Mmmol 0.232 0.927/0.927/0.927
mol/mol 1 4/4/4  Mol/mol 1 4/4/4
将 131mg 2,2,6,6-四甲基六氢吡啶加 1.5ml无水甲苯, 冷至 0*€ , 滴加 0.37ml 2.5M BuLi,加毕在 至 搅摔反应 30min, 然后滴加 1ml 0.9M Et2AlCl(甲苯)溶液, 加毕在 至 5"€搅拌反应 40min, 然后滴加含 70mg (0.232mmol)实施例 6的化合物的 1.5ml甲苯溶液,加毕 搅拌反应 20 小时。 TLC显示原料斑点消失, 小心滴加甲醇中止反应, 加饱和 NH4C1, 用乙醚萃取, 合并萃取液, 水洗, 无水 Na2S04干燥, 过滤, 滤液经硅胶 短柱纯化, 石油醚 /EtOAc(10/l)洗脱, 得产物 50mg (71.4%), Rf=0.35 (石 油醚 /EtOAc=4/l)。 Add 131mg of 2,2,6,6-tetramethylhexahydropyridine to 1.5ml of anhydrous toluene, cool to 0*€, add 0.37ml of 2.5M BuLi, add to the stirring reaction for 30min, then add 1ml A 0.9 M Et 2 AlCl (toluene) solution was added and stirred for 5 min to 5", then a solution of 70 mg (0.232 mmol) of the compound of Example 6 in 1.5 ml of toluene was added dropwise, and the reaction was stirred for 20 hours. The spot of the raw material disappears, carefully add methanol to stop the reaction, add saturated NH 4 C1, Extracted with ether, and the combined extracts were washed with water, dried over anhydrous Na 2 S0 4, filtered, and the filtrate was purified by a short column of silica gel, eluting with petroleum ether / EtOAc (10 / l), to give the product 50mg (71.4%), Rf = 0.35 (Petroleum ether / EtOAc = 4 / l).
[a]D 20 = -60 (c 0.33, CHC13); [a] D 20 = -60 (c 0.33, CHC1 3 );
JH NMR (300M, CDC13, ppm) δ 5.35 (s, 1H), 5.14 (s, 1H), 4.67 (s, 2H), 4.39 (s, 1H), 4.18 (s, 1H), 3.68-3.63 (m, 1H), 3.50-3.44 (m, 1H), 3.37 (s, 3H), 2.82 (s, 1H), 2.24-2.16 (m, 1H), 1.88-1.83 (m, 1H), 0.89 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H); J H NMR (300M, CDC1 3 , ppm) δ 5.35 (s, 1H), 5.14 (s, 1H), 4.67 (s, 2H), 4.39 (s, 1H), 4.18 (s, 1H), 3.68-3.63 (m, 1H), 3.50-3.44 (m, 1H), 3.37 (s, 3H), 2.82 (s, 1H), 2.24-2.16 (m, 1H), 1.88-1.83 (m, 1H), 0.89 (s , 9H), 0.05 (s, 3H), 0.04 (s, 3H);
13C NMR (125M, CDC13, ppm) δ 110.6, 95.1, 78.4, 74.6, 64.5, 55.4, 52.1, 40.4, 29.7, 25.8, 18.2, -5.5, -5.5。 13 C NMR (125M, CDC1 3 , ppm) δ 110.6, 95.1, 78.4, 74.6, 64.5, 55.4, 52.1, 40.4, 29.7, 25.8, 18.2, -5.5, -5.5.
HR-MS (ESI) 计算值 C15H3104SiNa (M+Na)+: 325.18351 , 实测值 325.18398. 实施例 8: 制备 (lR,3R,4S)-4- (叔丁基二甲基硅氧基) -3- ((叔丁基二甲基 硅 甲基) -2-亚甲基-环戊醇 (化合物 II, 其中 R=R,= t-Bu(Me)2Si-) HR-MS (ESI) calcd for C 15 H 31 0 4 SiNa ( M + Na) +: 325.18351, found 325.18398 Example 8: Preparation of (lR, 3R, 4S) -4- ( t-butyldimethyl Silyloxy)-3-((tert-butyldimethylsilylmethyl)-2-methylene-cyclopentanol (Compound II, where R=R, = t-Bu(Me) 2 Si-)
按照上述实施例 7的类似方法, 采用实施例 5制备的仲羟基硅保护的 化合物可得下述产物, 收率 92.5%。 According to the similar method of the above Example 7, the secondary hydroxysilicon-protected compound prepared in Example 5 was used to obtain the following product in a yield of 92.5%.
Figure imgf000032_0001
Figure imgf000032_0001
II  II
[a]D = -34 (c 0.44, CHC13); m.p.63-65"C [a] D = -34 (c 0.44, CHC1 3 ); mp63-65"C
JH NMR (300M, CDC13, ppm) δ 5.39 (s, 1H), 5.13 (s, 1H), 4.36 (m, 2H) 3.56 (dd, 1H, J=10.5, 5.1Hz), 3.31 (dd, 1H, J=10.2, 8.7Hz), 2.76 (m, 1H) 1.99 (ddd, 1H, J=13.2, 5.4, 4.5Hz), 1.82 (dq, 1H, J=13.2, 1.1Hz), 0.88 (s 18H), 0.09 (s, 6H), 0.04 (s, 3H), 0.03 (s, 3H); J H NMR (300M, CDC1 3 , ppm) δ 5.39 (s, 1H), 5.13 (s, 1H), 4.36 (m, 2H) 3.56 (dd, 1H, J=10.5, 5.1Hz), 3.31 (dd, 1H, J=10.2, 8.7Hz), 2.76 (m, 1H) 1.99 (ddd, 1H, J=13.2, 5.4, 4.5Hz), 1.82 (dq, 1H, J=13.2, 1.1Hz), 0.88 (s 18H) ), 0.09 (s, 6H), 0.04 (s, 3H), 0.03 (s, 3H);
13C NMR (75M, CDC13, ppm )δ 154.2, 111.7, 75.4, 75.3, 64.6, 54.9, 42.0 25.9, 25.8, 25.6, 18.2, 17.8, -4.8, -4.9, -5.5, -5.6. HR-MS (ESI)计算值 C19H4103Si 2(M+H)+: 373.2589,实测值 373.2585 实施例 9: 制备 9-((lS,3R,4S)-3- ((叔丁基二甲^ 甲基) -4- (甲氧 基甲氧基) -2-亚甲基环戊基 )-6-氯 -9H-嘌呤 -2-胺(化合物 8, 其中 R=CH3OCH2-, R'=t-Bu(Me)2Si-) 13 C NMR (75M, CDC1 3 , ppm ) δ 154.2, 111.7, 75.4, 75.3, 64.6, 54.9, 42.0 25.9, 25.8, 25.6, 18.2, 17.8, -4.8, -4.9, -5.5, -5.6. HR-MS (ESI) calcd for C 19 H 41 0 3 Si 2 (M + H) +: 373.2589, Found 373.2585 Example 9: Preparation of 9 - ((lS, 3R, 4S) -3- (( tert-butoxy Dimethyl(methyl)-4-(methoxymethoxy)-2-methylenecyclopentyl)-6-chloro-9H-indol-2-amine (Compound 8, wherein R=CH 3 OCH 2 -, R'=t-Bu(Me) 2 Si-)
Figure imgf000033_0001
Figure imgf000033_0001
Fw 302 169/262/174 453  Fw 302 169/262/174 453
Wt(mg) 150 210/262/175  Wt(mg) 150 210/262/175
mmol 0.5 1 .25/1 .0/1 .0  Mmol 0.5 1 .25/1 .0/1 .0
mol/mol 1 2.5/2/2  Mol/mol 1 2.5/2/2
150mg (0.5mmol) 实施例 7 制备的化合物 II (R=MOM, R,= t-BuMe2Si) 、 210mg (1.25mmol) 2-氨基 -6-氯-鸟嘌呤和 262mg Ph3P(1.0mmol)置 25ml圆底烧瓶中, 加 10ml无水 THF, 冷至 -23*€, 滴加 175mg (l.Ommol) DEAD, 加毕在 -23 "C至 0"C搅拌反应 8小时, 然后减压 蒸除 THF, 加 20ml甲基叔丁醚, 放置 2小时, 过滤除去不溶物, 滤液经 柱层折纯化, 石油醚 /EtOAc(10/l)洗脱, 得产物 151.7g (67%)。 150 mg (0.5 mmol) of compound II prepared in Example 7 (R = MOM, R, = t-BuMe 2 Si), 210 mg (1.25 mmol) 2-amino-6-chloro-guanine and 262 mg Ph 3 P (1.0 mmol Place a 25 ml round bottom flask, add 10 ml of anhydrous THF, cool to -23*€, add 175 mg (1.0 mmol) of DEAD, add the reaction at -23"C to 0"C for 8 hours, then decompress. The THF was evaporated, and EtOAc (EtOAc) (EtOAc)EtOAc.
[a]D 20 = +30 (c 0.105, CHC13); m.p. 157-160 °C [a] D 20 = +30 (c 0.105, CHC1 3 ); mp 157-160 °C
JH匪 R (300M, CDC13, ppm) δ 7.87 (s, 1H), 6.63 (s, 1H), 5.54 (m, 1H), 5.25 (s, 1H), 4.88 (s, 1H), 4.69 (s, 2H), 4.32 (m, 1H), 3.88-3.81 (m, 2H), 3.39 (s, 3H), 2.84 (s, 1H), 2.38-2.29 (s, 2H), 0.93 (s, 9H), 0.11 (s, 6H); J H匪R (300M, CDC1 3 , ppm) δ 7.87 (s, 1H), 6.63 (s, 1H), 5.54 (m, 1H), 5.25 (s, 1H), 4.88 (s, 1H), 4.69 ( s, 2H), 4.32 (m, 1H), 3.88-3.81 (m, 2H), 3.39 (s, 3H), 2.84 (s, 1H), 2.38-2.29 (s, 2H), 0.93 (s, 9H) , 0.11 (s, 6H);
13C匪 R (100M, CDCI3, ppm )δ 158.9, 153.9, 151.2, 148.5, 141.5, 111.5 95.1, 76.8, 64.3, 56.3, 55.5, 51.7, 38.0, 30.5,25.9, 18.4, -5.4. 13 C匪R (100M, CDCI3, ppm )δ 158.9, 153.9, 151.2, 148.5, 141.5, 111.5 95.1, 76.8, 64.3, 56.3, 55.5, 51.7, 38.0, 30.5, 25.9, 18.4, -5.4.
HR-MS (ESI)计算值 C2()H33ClN503Si (M+H)+: 454.2036, 实测值 454.2027 实施例 10: 9-((lS,3R,4S)-4- (叔丁基二甲 氧基) -3- ((叔丁基二甲羞 ¾ 氧基)甲基) -2-亚甲基环戊基 )-6-氯 -9H-嘌呤 -2-胺 (化合物 8, 其中 R=R,= t-Bu(Me)2Si-)的制备 HR-MS (ESI) calcd for C 2 () H 33 ClN 5 0 3 Si (M+H)+: 454.2036, measured value 454.2027 Example 10: 9-((lS,3R,4S)-4-(tert-Butyldimethoxy)-3-((tert-butyldimethyl 3 methoxy)methyl)-2-methyl Preparation of cyclopentyl)-6-chloro-9H-indol-2-amine (Compound 8, wherein R=R, = t-Bu(Me) 2 Si-)
按照上述实施例 9的类似方法, 采用实施例 8制备的仲羟基硅保护的 化合 II可得下述产物, 收率 61.3%。  According to the similar method of the above Example 9, the secondary hydroxysilicon-protected compound II prepared in Example 8 gave the following product in a yield of 61.3%.
[a]D = +33 (c 0.13, CHC13); 熔点 37-39 "C [a] D = +33 (c 0.13, CHC1 3 ); Melting point 37-39 "C
JH匪 R (300M, CDC13, ppm) δ 7.83 (s, 1H), 5.55-5.50 (m, 1H), 5.19 (s, 1H), 4.83 (s, 1H), 4.35-4.42 (m, 1H), 3.84-3.74 (m,2H), 2.67 (br s, 1H), 2.33-2.15 (m, 2H), 0.92 (s, 9H), 0.90 (s, 9H), 0.10 (s, 6H), 0.08 (s, 6H); J H匪R (300M, CDC1 3 , ppm) δ 7.83 (s, 1H), 5.55-5.50 (m, 1H), 5.19 (s, 1H), 4.83 (s, 1H), 4.35-4.42 (m, 1H) ), 3.84-3.74 (m, 2H), 2.67 (br s, 1H), 2.33-2.15 (m, 2H), 0.92 (s, 9H), 0.90 (s, 9H), 0.10 (s, 6H), 0.08 (s, 6H);
13C匪 R (125M, CDCI3, ppm )δ 158.8, 153.9, 151.1, 148.9, 141.8, 125.4 111.4, 72.4, 64.1, 56.3, 54.7, 40.4, 26.0, 25.8, 18.4, 18.0, -4.6, -4.7, -5.4, -5.4. 13 C匪R (125M, CDCI3, ppm )δ 158.8, 153.9, 151.1, 148.9, 141.8, 125.4 111.4, 72.4, 64.1, 56.3, 54.7, 40.4, 26.0, 25.8, 18.4, 18.0, -4.6, -4.7, - 5.4, -5.4.
HR-MS (ESI) 计算值 C24H43ClN502Si2 (M+H)+: 524.2638, 实测值 524.2635 实施例 11: 恩替卡韦的制备 HR-MS (ESI) calcd for C 24 H 43 ClN 5 0 2 Si 2 (M + H) +: 524.2638, found 524.2635 Example 11: Preparation of abacavir entecavir
Figure imgf000035_0001
Figure imgf000035_0001
Fw 453 277  Fw 453 277
Wt(mg) 450  Wt(mg) 450
450mg (lmmol)的实施例 9制备的化合物 8 [R=MOM,R,= t-BuMe2Si] 加 20ml 2N HC1和 20ml THF, 加热搅拌回流反应 8小时, 减压蒸除部分 THF, 残留水溶液用 20ml乙醚萃取, 水层用 2.5N NaOH调节 pH至 7, 室温放置过夜, 过滤, 少量水洗得到类白色固体。 上述产物用约 2ml水重 结晶, 得无白色结晶 172mg (62%)。 450 mg (1 mmol) of the compound 8 prepared in Example 9 [R = MOM, R, = t-BuMe 2 Si], 20 ml of 2N HCl and 20 ml of THF were added, and the mixture was stirred under reflux for 8 hours, and a portion of THF was evaporated under reduced pressure. It was extracted with 20 ml of diethyl ether. The aqueous layer was adjusted to pH 7 with 2.5N NaOH, and allowed to stand overnight at room temperature, filtered, and washed with a small amount of water to give an off-white solid. The above product was recrystallized from about 2 ml of water to give 172 mg (62%) of white crystals.
^NMR (d6-DMSO, 300ΜΗζ): δ = 2.03 (m,lH), 2.20 (m,lH), 3.51 (t,2H,J=6Hz), 4.21 (bs,lH), 4.54 (s,lH), 4.80-4.86 (m, 2H,可被 D20交换), 5.08 (s,l), 7.64 (s,lH,可被 D20交换变宽), 10.54 (s,lH)„ ^NMR (d 6 -DMSO, 300 ΜΗζ): δ = 2.03 (m, lH), 2.20 (m, lH), 3.51 (t, 2H, J = 6 Hz), 4.21 (bs, lH), 4.54 (s, lH) ), 4.80-4.86 (m, 2H, can be exchanged by D 2 0), 5.08 (s,l), 7.64 (s,lH, can be widened by D 2 0 exchange), 10.54 (s,lH)„
本发明提供的新制备方法与现有技术相比, 中间体容易纯化, 质量可 控, 而且其原料易得, 价格便宜, 更好地降低了生产成本。  Compared with the prior art, the novel preparation method provided by the invention is easy to purify, the quality is controllable, and the raw materials are easy to obtain, the price is cheap, and the production cost is better reduced.
上文提供了本发明的一些实施方案及其具体实例, 但本领域技术人员 可以理解, 这些实施方案与实例仅是对本发明的举例性描述, 在不背离本 发明的主旨的情况下, 可以对它们进行其他修饰和变换。  The embodiments of the present invention and the specific examples thereof are provided above, but those skilled in the art can understand that the embodiments and examples are merely illustrative of the present invention, and without departing from the gist of the present invention, They make other modifications and transformations.

Claims

权 利 right
1、 制备式 II化合物的方法,
Figure imgf000036_0001
1. A method of preparing a compound of formula II,
Figure imgf000036_0001
CH2〇R' CH 2 〇R'
II 其中  II where
R是羟基保护基, 选自: (i)烷基, (ii)芳烷基例如苄基, (iii)烷氧基亚 烷基, 例如烷氧基亚甲基, 如 MeOCH2-, (iv)芳烷氧基亚烷基, 例如芳烷 * ^亚甲基,如 BnOCH2-,或 (V)硅烷基,例如三苯基硅基、三异丙基硅基、 叔丁基二甲^ ^基、 叔丁基二苯^ ^基; R is a hydroxy protecting group selected from the group consisting of: (i) an alkyl group, (ii) an aralkyl group such as a benzyl group, (iii) an alkoxyalkylene group such as an alkoxymethylene group such as MeOCH 2 -, (iv An aralkoxyalkylene group, such as an aralkyl*^methylene group, such as BnOCH 2 -, or a (V) silane group, such as triphenylsilyl, triisopropylsilyl, tert-butyldimethyl ^Based, tert-butyldiphenyl ^ ^ group;
R,是羟基保护基, 选自: (i)芳烷基例如三苯甲基, 或 (ii)硅烷基, 例如 三苯 基、 三异丙 基、 叔丁基二甲 &、 叔丁 苯  R, which is a hydroxy protecting group, is selected from the group consisting of: (i) an aralkyl group such as a trityl group, or (ii) a silane group such as triphenyl, triisopropyl, tert-butyldimethyl, and tert-butylbenzene.
该方法包括以下步骤:  The method includes the following steps:
c)将化合物 3在 Grubbs催化剂存在下, 经烯烃复分解反应得到环状 化合物 4, c) the compound 3 is subjected to olefin metathesis reaction in the presence of a Grubbs catalyst to obtain a cyclic compound 4,
Figure imgf000036_0002
Figure imgf000036_0002
其中 R,如上文所定义,  Where R, as defined above,
d) 将化合物 4 与环氧化试剂在金属钒试剂催化下立体选择性地得到 环氧化中间体 5, d) stereoselectively obtaining an epoxidation intermediate 5 by catalyzing the compound 4 with an epoxidation reagent under a metal vanadium reagent,
Figure imgf000036_0003
Figure imgf000036_0003
5 e)将化合物 5的 物 6,5 e) the substance 6 of compound 5,
Figure imgf000037_0001
Figure imgf000037_0001
其中 X为卤素, R和 R,如上文所定义,  Wherein X is halogen, R and R, as defined above,
f)化合物 6在二烷基氯化铝试剂和 N,N-二烷基胺锂作用下环氧开环形 成中间体 II, f) compound 6 is epoxy-opened to form intermediate II under the action of a dialkylaluminum chloride reagent and lithium N,N-dialkylamine,
Figure imgf000037_0002
Figure imgf000037_0002
其中 R和 R,如上文所定义。  Where R and R are as defined above.
2、 权利要求 1的方法, 其中, 在步骤 c中, 反应的催化剂为 Grubbs 第一代或第二代催化剂, 用量为 0.1~20 eq%。  The method of claim 1, wherein in step c, the catalyst for the reaction is Grubbs first or second generation catalyst in an amount of from 0.1 to 20 eq%.
3、权利要求 1或 2的方法, 其中, 在步骤 d中, 使用金属钒的配位试 剂作为催化剂, 例如 VO(acac)2, 环氧化试剂选自叔丁基过氧化氢、 过氧 化氢、 间氯过氧苯甲酸、 过氧苯甲酸、 过氧甲酸、 过氧乙酸。 3. The method of claim 1 or 2, wherein in step d, a coordination reagent of a metal vanadium is used as a catalyst, such as VO(acac) 2 , and the epoxidizing agent is selected from the group consisting of t-butyl hydroperoxide and hydrogen peroxide. , m-chloroperoxybenzoic acid, peroxybenzoic acid, peroxycarboxylic acid, peracetic acid.
4、 权利要求 1至 3任意一项所述的方法, 其中, 在步骤 e中, 在化合 物 4的仲醇的保护试剂 RX中, R选自 BnOCH2-、MeOCH2-、t-Bu(Me)2Si -、 i-Pr3Si-和 t-BuPh2Si-; X为卤素, 例如 C1; 反应中使用的碱选自三乙胺、 二异丙基乙胺、 DBU、 咪唑等。 The method according to any one of claims 1 to 3, wherein, in the step e, in the protective reagent RX of the secondary alcohol of the compound 4, R is selected from the group consisting of BnOCH 2 -, MeOCH 2 -, t-Bu (Me 2 Si -, i-Pr 3 Si- and t-BuPh 2 Si-; X is a halogen such as C1; the base used in the reaction is selected from the group consisting of triethylamine, diisopropylethylamine, DBU, imidazole and the like.
5、 权利要求 1至 4任意一项所述的方法, 其中, 在步骤 f中, 二烷基 氯化铝试剂是例如二乙基氯化铝, N,N-二烷基胺锂由相应的二烷基胺经与 丁基锂反应原位制得, 其中二烷基胺选自 N,N-二异丙基胺、 N,N-二环己基 胺和 2,2,6,6-四甲基六氢吡啶。  The method according to any one of claims 1 to 4, wherein, in the step f, the dialkylaluminum chloride reagent is, for example, diethylaluminum chloride, N,N-dialkylamine lithium from the corresponding The dialkylamine is prepared in situ by reaction with butyllithium, wherein the dialkylamine is selected from the group consisting of N,N-diisopropylamine, N,N-dicyclohexylamine, and 2,2,6,6-tetra Methyl hexahydropyridine.
6、 权利要求 1至 5任意一项所述的方法, 其中: 在步骤 c中, 反应的催化剂为 Grubbs第一代或第二代催化剂, 用量 为 0.1 20 eq%; 6. The method of any one of claims 1 to 5, wherein: In step c, the catalyst for the reaction is Grubbs first or second generation catalyst, and the amount is 0.120 eq%;
在步骤 d中, 使用金属钒的配位试剂作为催化剂, 例如 VO(acac)2, 环氧化试剂选自叔丁基过氧化氢、 过氧化氢、 间氯过氧苯甲酸、 过氧苯甲 酸、 过氧甲酸、 过氧乙酸; In step d, a coordination reagent of metal vanadium is used as a catalyst, such as VO(acac) 2 , and the epoxidizing agent is selected from the group consisting of t-butyl hydroperoxide, hydrogen peroxide, m-chloroperoxybenzoic acid, and peroxybenzoic acid. , peroxyformic acid, peracetic acid;
在步骤 e中,在化合物 4的仲醇的保护试剂 RX中, R选自 BnOCH2-、 MeOCH2-、 t-Bu(Me)2Si -、 i-Pr3Si-和 t-BuPh2Si-; X为卤素, 例如 C1; 反 应中使用的碱选自三乙胺、 二异丙基乙胺、 DBU、 咪峻等; In the step e, in the protective reagent RX of the secondary alcohol of the compound 4, R is selected from the group consisting of BnOCH 2 -, MeOCH 2 -, t-Bu(Me) 2 Si -, i-Pr 3 Si- and t-BuPh 2 Si - X is a halogen, such as C1; the base used in the reaction is selected from the group consisting of triethylamine, diisopropylethylamine, DBU, imi, and the like;
在步骤 f 中, 二烷基氯化铝试剂是例如二乙基氯化铝, N,N-二烷 锂由相应的二烷基胺经与丁基锂反应原位制得, 其中二烷基胺选自 N,N- 二异丙基胺、 N,N-二环己基胺和 2,2,6,6-四甲基六氢吡啶。  In step f, the dialkyl aluminum chloride reagent is, for example, diethylaluminum chloride, and the N,N-dialkyllithium is prepared in situ from the corresponding dialkylamine by reaction with butyllithium, wherein the dialkyl group The amine is selected from the group consisting of N,N-diisopropylamine, N,N-dicyclohexylamine and 2,2,6,6-tetramethylhexahydropyridine.
7、权利要求 1至 6中任意一项所述的方法,其中用化合物 4作为原料 并进行其中所述的步骤 d)到 f)。  The method according to any one of claims 1 to 6, wherein the compound 4 is used as a raw material and the steps d) to f) described therein are carried out.
8、权利要求 1至 6中任意一项所述的方法,其中用化合物 5作为原料 并进行其中所述的步骤 e)到 f)。  The method according to any one of claims 1 to 6, wherein the compound 5 is used as a raw material and the steps e) to f) described therein are carried out.
9、权利要求 1至 6中任意一项所述的方法,其中用化合物 6作为原料 直接进行步骤 f)。  The method according to any one of claims 1 to 6, wherein the step f) is directly carried out using the compound 6 as a raw material.
10、 根据权利要求 1所述的 II的合成方法,  10. The method of synthesizing II according to claim 1,
Figure imgf000038_0001
Figure imgf000038_0001
R是羟基保护基, 选自: (i)烷基, (ii)芳烷基例如苄基, (iii)烷氧基亚 烷基, 例如烷氧基亚甲基, 如 MeOCH2-, (iv)芳烷氧基亚烷基, 例如芳烷 亚甲基,如 BnOCH2-,或 (V)硅烷基,例如三苯基¾、三异丙基硅基、 叔丁基二甲 基、 叔丁基二苯^ ^基; R,是羟基保护基, 选自: (i)芳烷基例如三苯甲基, 或 (ii)硅烷基, 例如 三苯^:基、 三异丙 基、 叔丁基二甲^:基、 叔丁^!苯^:基; 该方法包括以下步骤: R is a hydroxy protecting group selected from the group consisting of: (i) an alkyl group, (ii) an aralkyl group such as a benzyl group, (iii) an alkoxyalkylene group such as an alkoxymethylene group such as MeOCH 2 -, (iv An aralkoxyalkylene group, such as an aralkylmethylene group, such as a BnOCH 2 -, or a (V) silane group, such as triphenyl 3⁄4, triisopropylsilyl, tert-butyldimethyl, tert-butyl Diphenylene ^ ^ group; R, is a hydroxy protecting group, selected from: (i) an aralkyl group such as a trityl group, or (ii) a silane group, such as a triphenyl group, a triisopropyl group, a t-butyl dimethyl group: Uncle Ding ^! Benzene: base; the method comprises the following steps:
a) 中间体化合物 1经与异丙烯格氏试剂在卤化亚铜存在下反应得到化 合物 2  a) Intermediate compound 1 is reacted with isopropenol Grignard reagent in the presence of cuprous halide to obtain compound 2
Figure imgf000039_0001
Figure imgf000039_0001
其中 X为卤素或氰基,  Wherein X is a halogen or a cyano group,
b)将化合物 择性保护得化合 3,  b) selective compounding of the compound 3,
Figure imgf000039_0002
Figure imgf000039_0002
其中 R,如上文所定义, X为卤素,  Where R, as defined above, X is a halogen,
c)将化合物 3在 Grubbs催化剂存在下, 经烯烃复分解反应得到环状 化合物 4,
Figure imgf000039_0003
c) the compound 3 is subjected to olefin metathesis reaction in the presence of a Grubbs catalyst to obtain a cyclic compound 4,
Figure imgf000039_0003
其中 R,如上文所定义,  Where R, as defined above,
d) 将化合物 4 与环氧化试剂在金属钒试剂催化下立体选择性地得到 环氧化中间体 5, d) stereoselectively obtaining an epoxidation intermediate 5 by catalyzing the compound 4 with an epoxidation reagent under a metal vanadium reagent,
Figure imgf000039_0004
Figure imgf000039_0004
5 e)将化合物 5的 物 6, 5 e) the substance 6 of compound 5,
Figure imgf000040_0001
Figure imgf000040_0001
其中 X为卤素, R和 R,如上文所定义,  Wherein X is halogen, R and R, as defined above,
f)化合物 6在二烷基氯化铝试剂和 N,N-二烷基胺锂作用下环氧开环形 成中间体 II,  f) compound 6 is epoxy-opened to form intermediate II under the action of a dialkylaluminum chloride reagent and lithium N,N-dialkylamine,
Figure imgf000040_0002
Figure imgf000040_0002
其中 R和 R,如上文所定义。  Where R and R are as defined above.
11、权利要求 10的方法,其中,在步骤 a中, 卤化亚铜试剂选自 Cul、 CuBr或 CuBr.Me2S。 11. The method of claim 10 wherein in step a the cuprous halide agent is selected from the group consisting of Cul, CuBr or CuBr.Me 2 S.
12、 权利要求 10或 11的方法, 其中, 在步骤 b中, 伯羟基保护试剂 R,X选自三苯基氯化硅、 三异丙基氯化硅、 叔丁基二甲基氯化硅、 叔丁基 二苯基氯化硅、 三苯基氯甲烷, 碱为有 例如三乙胺、 DBU、 咪唑、 二异丙基乙胺。  12. The method of claim 10 or 11, wherein in step b, the primary hydroxyl protecting agent R, X is selected from the group consisting of triphenylsilyl chloride, triisopropylsilyl chloride, tert-butyldimethylsilyl chloride , tert-butyl diphenyl silicon chloride, triphenylchloromethane, and the base is, for example, triethylamine, DBU, imidazole, diisopropylethylamine.
13、 权利要求 10-12任意一项的方法, 其中, 在步骤 c中, 反应的催 化剂为 Grubbs第一代或第二代催化剂, 用量为 0.1~20 eq%。  The process according to any one of claims 10 to 12, wherein, in the step c, the catalyst for the reaction is a Grubbs first or second generation catalyst in an amount of from 0.1 to 20 eq%.
14、 权利要求 10-13任意一项的方法, 其中, 在步骤 d中, 使用金属 钒的配位试剂作为催化剂, 例如 VO(acac)2, 环氧化试剂选自叔丁基过氧 化氢、 过氧化氢、 间氯过氧苯甲酸、 过氧苯甲酸、 过氧甲酸、 过氧乙酸。 14. The method of any of claims 10-13, wherein in step d, a coordination reagent of a metal vanadium is used as a catalyst, such as VO(acac) 2 , and the epoxidizing agent is selected from the group consisting of t-butyl hydroperoxide, Hydrogen peroxide, m-chloroperoxybenzoic acid, peroxybenzoic acid, peroxycarboxylic acid, peracetic acid.
15、 权利要求 10-14任意一项所述的方法, 其中, 在步骤 e中, 在化 合物 4 的仲醇的保护试剂 RX 中, R 选自 BnOCH2-、 MeOCH2-、 t-Bu(Me)2Si -、 i-Pr3Si-和 t-BuPh2Si-; X为卤素, 例如 C1; 反应中使用的 碱选自三乙胺、 二异丙基乙胺、 DBU、 咪唑等。 The method according to any one of claims 10 to 14, wherein, in the step e, in the protective reagent RX of the secondary alcohol of the compound 4, R is selected from the group consisting of BnOCH 2 -, MeOCH 2 -, t-Bu (Me 2 Si -, i-Pr 3 Si- and t-BuPh 2 Si-; X is a halogen, such as C1; used in the reaction The base is selected from the group consisting of triethylamine, diisopropylethylamine, DBU, imidazole and the like.
16、 权利要求 10-15任意一项所述的方法, 其中, 在步骤 f 中, 二烷 基氯化铝试剂是例如二乙基氯化铝, N,N-二烷基胺锂由相应的二烷基胺经 与丁基锂反应原位制得, 其中二烷基胺选自 N,N-二异丙基胺、 N,N-二环己 ^^和 2,2,6,6-四甲基六氢吡啶。  The method according to any one of claims 10 to 15, wherein in the step f, the dialkylaluminum chloride reagent is, for example, diethylaluminum chloride, N,N-dialkylamine lithium by the corresponding The dialkylamine is prepared in situ by reaction with butyllithium, wherein the dialkylamine is selected from the group consisting of N,N-diisopropylamine, N,N-dicyclohexanyl and 2,2,6,6- Tetramethylhexahydropyridine.
17、 权利要求 10至 16任意一项所述的方法, 其中:  17. The method of any of claims 10 to 16, wherein:
在步骤 a中, 卤化亚铜试剂选自 Cul、 CuBr或 CuBr.Me2S; In step a, the cuprous halide reagent is selected from Cul, CuBr or CuBr.Me 2 S;
在步骤 b中, 伯羟基保护试剂 R,X选自三苯基氯化硅、 三异丙基氯化 硅、 叔丁基二甲基氯化硅、 叔丁基二苯基氯化硅、 三苯基氯甲烷, 碱为有 机喊, 例如三乙胺、 DBU、 咪唑、 二异丙基乙胺;  In step b, the primary hydroxyl protecting agent R, X is selected from the group consisting of triphenylsilyl chloride, triisopropylsilyl chloride, tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride, three Phenylchloromethane, the base is organically called, such as triethylamine, DBU, imidazole, diisopropylethylamine;
在步骤 c中, 反应的催化剂为 Grubbs第一代或第二代催化剂, 用量 为 0.1 20 eq%;  In step c, the catalyst for the reaction is Grubbs first or second generation catalyst, and the amount is 0.120 eq%;
在步骤 d中, 使用金属钒的配位试剂作为催化剂, 例如 VO(acac)2, 环氧化试剂选自叔丁基过氧化氢、 过氧化氢、 间氯过氧苯甲酸、 过氧苯甲 酸、 过氧甲酸、 过氧乙酸; In step d, a coordination reagent of metal vanadium is used as a catalyst, such as VO(acac) 2 , and the epoxidizing agent is selected from the group consisting of t-butyl hydroperoxide, hydrogen peroxide, m-chloroperoxybenzoic acid, and peroxybenzoic acid. , peroxyformic acid, peracetic acid;
在步骤 e中,在化合物 4的仲醇的保护试剂 RX中, R选自 BnOCH2-、 MeOCH2-、 t-Bu(Me)2Si -、 i-Pr3Si-和 t-BuPh2Si-; X为卤素, 例如 C1; 反 应中使用的碱选自三乙胺、 二异丙基乙胺、 DBU、 咪峻等; In the step e, in the protective reagent RX of the secondary alcohol of the compound 4, R is selected from the group consisting of BnOCH 2 -, MeOCH 2 -, t-Bu(Me) 2 Si -, i-Pr 3 Si- and t-BuPh 2 Si - X is a halogen, such as C1; the base used in the reaction is selected from the group consisting of triethylamine, diisopropylethylamine, DBU, imi, and the like;
在步骤 f 中, 二烷基氯化铝试剂是例如二乙基氯化铝, N,N-二烷 锂由相应的二烷基胺经与丁基锂反应原位制得, 其中二烷基胺选自 N,N- 二异丙 ^胺、 N,N-二环己基胺和 2,2,6,6-四甲基六氢吡啶。  In step f, the dialkyl aluminum chloride reagent is, for example, diethylaluminum chloride, and the N,N-dialkyllithium is prepared in situ from the corresponding dialkylamine by reaction with butyllithium, wherein the dialkyl group The amine is selected from the group consisting of N,N-diisopropylamine, N,N-dicyclohexylamine and 2,2,6,6-tetramethylhexahydropyridine.
18、 权利要求 10至 17中任意一项所述的方法, 其中用化合物 2作为 原料并进行其中所述的步骤 b)到 f)。  The method according to any one of claims 10 to 17, wherein the compound 2 is used as a raw material and the steps b) to f) described therein are carried out.
19、 式 V的化合物:  19. Compounds of formula V:
Figure imgf000041_0001
其中
Figure imgf000041_0001
among them
R是氢或羟基保护基, 选自: (i)烷基, (ii)芳烷基例如苄基, (iii)烷氧 基亚烷基, 例如烷氧基亚甲基, 如 MeOCH2-, (iv)芳烷氧基亚烷基, 例如 芳烷氧基亚甲基, 如 BnOCH2-, 或 (V)硅烷基, 例如三苯^ ^基、 三异丙基 硅基、 叔丁^ 甲 基、 叔丁^苯 基; R is a hydrogen or hydroxy protecting group selected from the group consisting of: (i) an alkyl group, (ii) an aralkyl group such as a benzyl group, (iii) an alkoxyalkylene group such as an alkoxymethylene group such as MeOCH 2 -, (iv) an aralkoxyalkylene group, such as an aralkyloxymethylene group, such as a BnOCH 2 -, or a (V) silane group, such as a triphenylene group, a triisopropylsilyl group, a tert-butyl group Base, tert-butyl phenyl;
R,是羟基保护基, 选自: (i)芳烷基例如三苯甲基, 或 (ii)硅烷基, 例如 三苯^:基、 三异丙 基、 叔丁基二甲^:基、 叔丁^!苯^:基。  R, is a hydroxy protecting group, selected from: (i) an aralkyl group such as a trityl group, or (ii) a silane group, such as a triphenyl group, a triisopropyl group, a t-butyl dimethyl group: Uncle Ding ^! Benzene ^: base.
20、 权利要求 19的化合物, 其选自:  20. A compound of claim 19 selected from the group consisting of:
叔丁基(((18,211,38,511)-3-(甲氧基甲氧基)-1-甲基-6-氧杂-二环[3.1.0】己 tert-Butyl ((18,211,38,511)-3-(methoxymethoxy)-1-methyl-6-oxa-bicyclo[3.1.0]
-2-基)甲 *J 二甲 燒, -2-yl) A *J dimethyl burning,
(1S,2R,3S,5R)_3- (叔丁基二甲基硅氧基) -2- ((叔丁基二甲基硅氧基)甲 基) -1-甲基 -6-氧杂 -二环 [3.1.0】己烷, (1S, 2 R, 3 S, 5 R)_ 3 - (tert-Butyldimethylsilyloxy)-2-((tert-butyldimethylsilyloxy)methyl)-1-methyl- 6-oxa-bicyclo[3.1.0]hexane,
(lS,2R,3S,5R)-2- ((叔丁基二甲基硅氧基)甲基) -1-甲基 -6-氧杂 -二环  (lS, 2R, 3S, 5R)-2-((tert-butyldimethylsilyloxy)methyl)-1-methyl-6-oxa-bicyclo
[3丄0】己 -3-醇。  [3丄0]hex-3-ol.
21、 制备如权利要求 19所 方法,  21. The method of claim 19,
Figure imgf000042_0001
Figure imgf000042_0001
其中 R和 R,如权利要求 19所述,  Wherein R and R are as recited in claim 19,
该方法包括以下步骤:  The method includes the following steps:
a) 中间体化合物 1经与异丙烯格氏试剂在卤化亚铜存在下反应得到化 合物 2  a) Intermediate compound 1 is reacted with isopropenol Grignard reagent in the presence of cuprous halide to obtain compound 2
Figure imgf000042_0002
Figure imgf000042_0002
其中 X为卤素或氰基,  Wherein X is a halogen or a cyano group,
b)将化合物 2的伯羟基选择性保护得化合物 3,
Figure imgf000043_0001
b) selectively protecting the primary hydroxyl group of compound 2 to give compound 3,
Figure imgf000043_0001
其中 R,如权利要求 19所述, X为卤素,  Wherein R, as recited in claim 19, X is a halogen,
c)将化合物 3在 Grubbs催化剂存在下, 经烯烃复分解反应得到环状 化合物 4,  c) the compound 3 is subjected to olefin metathesis reaction in the presence of a Grubbs catalyst to obtain a cyclic compound 4,
Figure imgf000043_0002
Figure imgf000043_0002
其中 R,如权利要求 19所述,  Where R, as recited in claim 19,
d) 将化合物 4 与环氧化试剂在金属钒试剂催化下立体选择性地得到 其中 R是氢的式 V化合物,  d) stereoselectively obtaining a compound of the formula V wherein R is hydrogen, by catalyzing the compound 4 with an epoxidizing reagent under the catalysis of a metal vanadium reagent,
Figure imgf000043_0003
Figure imgf000043_0003
其中 R是氢, R,如权利要求 19所述,  Wherein R is hydrogen, R, as recited in claim 19,
或者  Or
e)将其中 R是氢的式 V化合物的仲醇进行保护得到其中 R不是氢的 式 V化合物,  e) protecting a secondary alcohol of a compound of formula V wherein R is hydrogen to give a compound of formula V wherein R is not hydrogen,
Figure imgf000043_0004
Figure imgf000043_0004
其中 X为卤素, R和 R,如权利要求 19所述, 且 R不是氢。  Wherein X is halogen, R and R, as recited in claim 19, and R is not hydrogen.
22、权利要求 21的方法,其中,在步骤 a中, 卤化亚铜试剂选自 Cul、 CuBr或 CuBr.Me2S。 22. The method of claim 21 wherein in step a the cuprous halide reagent is selected from the group consisting of Cul, CuBr or CuBr.Me 2 S.
23、 权利要求 21或 22的方法, 其中, 在步骤 b中, 伯羟基保护试剂 R,X选自三苯基氯化硅、 三异丙基氯化硅、 叔丁基二甲基氯化硅、 叔丁基 二苯基氯化硅、 三苯基氯甲垸, 碱为有; M¾, 例如三乙胺、 DBU、 咪唑、 二异丙基乙胺。  23. The method of claim 21 or 22, wherein in step b, the primary hydroxyl protecting agent R, X is selected from the group consisting of triphenylsilyl chloride, triisopropylsilyl chloride, tert-butyldimethylsilyl chloride , tert-butyldiphenylsilyl chloride, triphenylchloroformamidine, a base; M3⁄4, such as triethylamine, DBU, imidazole, diisopropylethylamine.
24、 权利要求 21-23任意一项的方法, 其中, 在步骤 c中, 反应的催 化剂为 Grubbs第一代或第二代催化剂, 用量为 0.1~20 eq%。  The method according to any one of claims 21 to 23, wherein, in the step c, the catalyst for the reaction is a Grubbs first or second generation catalyst in an amount of from 0.1 to 20 eq%.
25、 权利要求 21-24任意一项的方法, 其中, 在步骤 d中, 使用金属 瓴的配位试剂作为催化剂, 例如 VO(acac)2, 环氧化试剂选自叔丁基过氧 化氢、 过氧化氢、 间氯过氧苯甲酸、 过氧苯甲酸、 过氧甲酸、 过氧乙酸。 The method according to any one of claims 21 to 24, wherein, in the step d, a coordination reagent of a metal ruthenium is used as a catalyst, for example, VO(acac) 2 , and the epoxidizing agent is selected from t-butyl hydroperoxide, Hydrogen peroxide, m-chloroperoxybenzoic acid, peroxybenzoic acid, peroxycarboxylic acid, peracetic acid.
26、 权利要求 21-25任意一项所述的方法, 其中, 在步骤 e中, 在化 合物 4 的仲醇的保护试剂 RX 中, R 选自 BnOCH2-、 MeOCH2-、 t-Bu(Me)2Si -、 i-Pr3Si-和 t-BuPh2Si-; X为卤素, 例如 C1; 反应中使用的 碱选自三乙胺、 二异丙基乙胺、 DBU、 咪唑等。 The method according to any one of claims 21 to 25, wherein, in the step e, in the protective reagent RX of the secondary alcohol of the compound 4, R is selected from the group consisting of BnOCH 2 -, MeOCH 2 -, t-Bu (Me 2 Si -, i-Pr 3 Si- and t-BuPh 2 Si-; X is a halogen such as C1; the base used in the reaction is selected from the group consisting of triethylamine, diisopropylethylamine, DBU, imidazole and the like.
27、 权利要求 21至 26任意一项所述的方法, 其中:  27. The method of any of claims 21 to 26, wherein:
在步骤 a中, 卤化亚铜试剂选自 Cul、 CuBr或 CuBr.Me2S; In step a, the cuprous halide reagent is selected from Cul, CuBr or CuBr.Me 2 S;
在步骤 b中, 伯羟基保护试剂 R,X选自三苯基氯化硅、 三异丙基氯化 硅、 叔丁基二甲基氯化硅、 叔丁基二苯基氯化硅、 三苯基氯甲烷, 碱为有 机喊, 例如三乙胺、 DBU、 咪唑、 二异丙基乙胺;  In step b, the primary hydroxyl protecting agent R, X is selected from the group consisting of triphenylsilyl chloride, triisopropylsilyl chloride, tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride, three Phenylchloromethane, the base is organically called, such as triethylamine, DBU, imidazole, diisopropylethylamine;
在步骤 c中, 反应的催化剂为 Grubbs第一代或第二代催化剂, 用量 为 0.1 20 eq%;  In step c, the catalyst for the reaction is Grubbs first or second generation catalyst, and the amount is 0.120 eq%;
在步骤 d中, 使用金属钒的配位试剂作为催化剂, 例如 VO(acac)2, 环氧化试剂选自叔丁基过氧化氢、 过氧化氢、 间氯过氧苯甲酸、 过氧苯甲 酸、 过氧甲酸、 过氧乙酸; In step d, a coordination reagent of metal vanadium is used as a catalyst, such as VO(acac) 2 , and the epoxidizing agent is selected from the group consisting of t-butyl hydroperoxide, hydrogen peroxide, m-chloroperoxybenzoic acid, and peroxybenzoic acid. , peroxyformic acid, peracetic acid;
在步骤 e中,在化合物 4的仲醇的保护试剂 RX中, R选自 BnOCH2-、 MeOCH2-、 t-Bu(Me)2Si -、 i-Pr3Si-和 t-BuPh2Si-; X为卤素, 例如 C1; 反 应中使用的碱选自三乙胺、 二异丙基乙胺、 DBU、 咪峻等。 In the step e, in the protective reagent RX of the secondary alcohol of the compound 4, R is selected from the group consisting of BnOCH 2 -, MeOCH 2 -, t-Bu(Me) 2 Si -, i-Pr 3 Si- and t-BuPh 2 Si - X is a halogen, for example, C1; the base used in the reaction is selected from the group consisting of triethylamine, diisopropylethylamine, DBU, milidine, and the like.
28、 权利要求 21至 27中任意一项所述的方法, 其中用化合物 2作为 原料并进行其中所述的步骤 b)到 e)。 The method according to any one of claims 21 to 27, wherein compound 2 is used as The raw materials are subjected to steps b) to e) described therein.
29、 权利要求 21至 27中任意一项所述的方法, 其中用化合物 3作为 原料并进行其中所述的步骤 c)到 e)。  The method according to any one of claims 21 to 27, wherein the compound 3 is used as a raw material and the steps c) to e) described therein are carried out.
30、 式 4的化合物:  30. Compound of formula 4:
Figure imgf000045_0001
Figure imgf000045_0001
其中 R,是羟基保护基, 选自: (i)芳烷基例如三苯甲基, 或 (ii)硅烷基, 例如三苯^^基、三异丙 基、叔丁^ 甲^^基、叔丁基二苯^ ¾基。  Wherein R is a hydroxy protecting group selected from the group consisting of: (i) an aralkyl group such as a trityl group, or (ii) a silane group, such as a triphenyl group, a triisopropyl group, a t-butyl group, a methyl group, Tert-butyldiphenyl^3⁄4 base.
31、 权利要求 30的化合物, 其选自:  31. The compound of claim 30 which is selected from the group consisting of:
(1S,2R)_2_ ((叔丁基二甲 J¾氧基)甲基) _3_甲基环戊 _3_烯 -1-醇。 (1S, 2 R) _ 2 _ (( tert-butyl-dimethoxy J¾) methyl) 3 _ _ _ 3 _ methylcyclopentadienyl-1-ol.
32、 制备如权利要求 30所 物的方法:  32. A method of preparing the method of claim 30:
Figure imgf000045_0002
Figure imgf000045_0002
其中 R,如权利要求 30所述,  Where R is as recited in claim 30,
该方法包括以下步骤:  The method includes the following steps:
a) 中间体化合物 1经与异丙烯格氏试剂在卤化亚铜存在下反应得到化 合物 2  a) Intermediate compound 1 is reacted with isopropenol Grignard reagent in the presence of cuprous halide to obtain compound 2
Figure imgf000045_0003
Figure imgf000045_0003
其中 X为卤素或氰基,  Wherein X is a halogen or a cyano group,
b)将化合物 2的伯羟基选择性保护得化合物 3,
Figure imgf000046_0001
b) selectively protecting the primary hydroxyl group of compound 2 to give compound 3,
Figure imgf000046_0001
其中 R,如权利要求 30所述, X为卤素,  Wherein R, as recited in claim 30, X is a halogen,
c)将化合物 3在 Grubbs催化剂存在下, 经烯烃复分解反应得到环状 化合物 4,  c) the compound 3 is subjected to olefin metathesis reaction in the presence of a Grubbs catalyst to obtain a cyclic compound 4,
Figure imgf000046_0002
Figure imgf000046_0002
其中 R,如权利要求 30所述。  Where R is as set forth in claim 30.
33、权利要求 32的方法,其中,在步骤 a中, 卤化亚铜试剂选自 Cul、 CuBr或 CuBr.Me2S。 33. The method of claim 32 wherein in step a the cuprous halide agent is selected from the group consisting of Cul, CuBr or CuBr. Me 2 S.
34、 权利要求 32或 33的方法, 其中, 在步骤 b中, 伯羟基保护试剂 R,X选自三苯基氯化硅、 三异丙基氯化硅、 叔丁基二甲基氯化硅、 叔丁基 二苯基氯化硅、 三苯基氯甲烷, 碱为有; M¾, 例如三乙胺、 DBU、 咪唑、 二异丙基乙胺。  34. The method of claim 32 or 33, wherein in step b, the primary hydroxyl protecting agent R, X is selected from the group consisting of triphenylsilyl chloride, triisopropylsilyl chloride, tert-butyldimethylsilyl chloride , tert-butyl diphenyl chloride, triphenylchloromethane, a base; M3⁄4, such as triethylamine, DBU, imidazole, diisopropylethylamine.
35、 权利要求 32-34任意一项的方法, 其中, 在步骤 c中, 反应的催 化剂为 Grubbs第一代或第二代催化剂, 用量为 0.1~20 eq%。  The method according to any one of claims 32 to 34, wherein in the step c, the catalyst for the reaction is Grubbs first or second generation catalyst in an amount of from 0.1 to 20 eq%.
36、 权利要求 32至 35任意一项所述的方法, 其中:  36. The method of any of claims 32 to 35, wherein:
在步骤 a中, 卤化亚铜试剂选自 Cul、 CuBr或 CuBr.Me2S; In step a, the cuprous halide reagent is selected from Cul, CuBr or CuBr.Me 2 S;
在步骤 b中, 伯羟基保护试剂 R,X选自三苯基氯化硅、 三异丙基氯化 硅、 叔丁基二甲基氯化硅、 叔丁基二苯基氯化硅、 三苯基氯甲烷, 碱为有 机减, 例如三乙胺、 DBU、 咪唑、 二异丙基乙胺;  In step b, the primary hydroxyl protecting agent R, X is selected from the group consisting of triphenylsilyl chloride, triisopropylsilyl chloride, tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride, three Phenylchloromethane, the base is organically reduced, such as triethylamine, DBU, imidazole, diisopropylethylamine;
在步骤 c中, 反应的催化剂为 Grubbs第一代或第二代催化剂, 用量 为 0.1 20 eq%。  In step c, the catalyst for the reaction is Grubbs first or second generation catalyst in an amount of 0.120 eq%.
37、 权利要求 32至 36中任意一项所述的方法, 其中用化合物 2作为 原料并进行其中所述的步骤 b)到 C)。 37. The method of any one of claims 32 to 36, wherein compound 2 is used as The raw materials are subjected to steps b) to C) described therein.
38、 权利要求 32至 37中任意一项所述的方法, 其中用化合物 3作为 原料并进行其中所述的步骤 c)。  The method according to any one of claims 32 to 37, wherein the compound 3 is used as a raw material and the step c) described therein is carried out.
39、 式 III的化合物:  39. Compounds of formula III:
Figure imgf000047_0001
Figure imgf000047_0001
其中 R,是氢或羟基保护基, 选自: (i)芳烷基例如三苯甲基, 或 (ii)硅烷 基, 例如三苯^^基、 三异丙^ ^基、 叔丁基二甲^ ^基、 叔丁基二苯基 硅基。  Wherein R is a hydrogen or hydroxy protecting group selected from the group consisting of: (i) an aralkyl group such as a trityl group, or (ii) a silane group such as a triphenyl group, a triisopropyl group, a tert-butyl group A ^ ^ base, tert-butyl diphenyl silicon.
40、 权利要求 39的化合物, 其选自:  40. The compound of claim 39 which is selected from the group consisting of:
(3R,4S)-3- ((叔丁基二甲 J¾氧基)甲基) -2-甲基庚 -1,6-二烯 -4-醇,  (3R,4S)-3-((tert-Butyldimethyl J3⁄4oxy)methyl)-2-methylheptan-1,6-dien-4-ol,
(2R,3S)-2- (丙 -1-烯 -2-基)己 -5-烯 -1,3-二醇。  (2R,3S)-2-(prop-1-en-2-yl)hex-5-ene-1,3-diol.
41、 制备式 III化合物  41. Preparation of a compound of formula III
Figure imgf000047_0002
Figure imgf000047_0002
其中 R,如权利要求 39所述,  Where R is as recited in claim 39,
该方法包括以下步骤:  The method includes the following steps:
a) 中间体化合物 1经与异丙烯格氏试剂在卤化亚铜存在下反应得到其 中 R,是氢的式  a) intermediate compound 1 is reacted with isopropenol Grignard reagent in the presence of cuprous halide to obtain R, which is hydrogen
Figure imgf000047_0003
Figure imgf000047_0003
其中 X为卤素或氰基,  Wherein X is a halogen or a cyano group,
或者 b)将其中 R,是氢的式 III化合物的伯羟基选择性保护得到其中 R,不 是氢的式 III化合 or b) selective protection of the primary hydroxyl group of the compound of formula III wherein R is hydrogen to give a compound of formula III wherein R is not hydrogen
Figure imgf000048_0001
Figure imgf000048_0001
其中 R,如权利要求 39所述, 且 R,不是氢, X为卤素。  Wherein R is as defined in claim 39, and R is not hydrogen and X is a halogen.
42、权利要求 41的方法,其中,在步骤 a中, 卤化亚铜试剂选自 Cul、 CuBr或 CuBr.Me2S。 42. The method of claim 41 wherein in step a the cuprous halide reagent is selected from the group consisting of Cul, CuBr or CuBr. Me 2 S.
43、 权利要求 41或 42的方法, 其中, 在步骤 b中, 伯羟基保护试剂 R,X选自三苯基氯化硅、 三异丙基氯化硅、 叔丁基二甲基氯化硅、 叔丁基 二苯基氯化硅、 三苯基氯甲烷, 碱为有 , 例如三乙胺、 DBU、 咪唑、 二异丙基乙胺。  43. The method of claim 41 or 42, wherein in step b, the primary hydroxyl protecting agent R, X is selected from the group consisting of triphenylsilyl chloride, triisopropylsilyl chloride, tert-butyldimethylsilyl chloride , tert-butyldiphenylsilyl chloride, triphenylchloromethane, a base such as triethylamine, DBU, imidazole, diisopropylethylamine.
44、 权利要求 41至 43任意一项所述的方法, 其中:  44. The method of any of claims 41 to 43, wherein:
在步骤 a中, 卤化亚铜试剂选自 Cul、 CuBr或 CuBr.Me2S; In step a, the cuprous halide reagent is selected from Cul, CuBr or CuBr.Me 2 S;
在步骤 b中, 伯羟基保护试剂 R,X选自三苯基氯化硅、 三异丙基氯化 硅、 叔丁基二甲基氯化硅、 叔丁基二苯基氯化硅、 三苯基氯甲烷, 碱为有 机减, 例如三乙胺、 DBU、 咪唑、 二异丙基乙胺。  In step b, the primary hydroxyl protecting agent R, X is selected from the group consisting of triphenylsilyl chloride, triisopropylsilyl chloride, tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride, three Phenylchloromethane, the base is organically reduced, such as triethylamine, DBU, imidazole, diisopropylethylamine.
45、权利要求 41至 44中任意一项所述的方法,其中用 R,是氢的式 III 化合物作为原料并进行其中所述的步骤 b)。  The method of any one of claims 41 to 44, wherein R, a compound of formula III which is hydrogen is used as a starting material and step b) is carried out therein.
46、 制备式 I化合物的方法,  46. A method of preparing a compound of formula I,
Figure imgf000048_0002
Figure imgf000048_0002
该方法包括以下步骤: c)将化合物 3在 Grubbs催化剂存在下, 经烯烃复分解反应得到环状 化合物 4,The method includes the following steps: c) the compound 3 is subjected to olefin metathesis reaction in the presence of a Grubbs catalyst to obtain a cyclic compound 4,
Figure imgf000049_0001
Figure imgf000049_0001
其中 R,如权利要求 1所定义,  Where R is as defined in claim 1
d) 将化合物 4 与环氧化试剂在金属钒试剂催化下立体选择性地得到 环氧化中间体 5,  d) stereoselectively obtaining an epoxidation intermediate 5 by catalyzing the compound 4 with an epoxidation reagent under a metal vanadium reagent,
Figure imgf000049_0002
Figure imgf000049_0002
其中 R,如权利要求 1所定义,  Where R is as defined in claim 1
e)将化合物 5的 物 6,
Figure imgf000049_0003
e) the substance 6 of compound 5,
Figure imgf000049_0003
其中 X为卤素, R和 R,如权利要求 1所定义,  Wherein X is halogen, R and R, as defined in claim 1,
f)化合物 6在二烷基氯化铝试剂和 N,N-二烷基胺锂作用下环氧开环形 成中间体 II,
Figure imgf000049_0004
f) compound 6 is epoxy ring-opened to form intermediate II under the action of a dialkylaluminum chloride reagent and lithium N,N-dialkylamine,
Figure imgf000049_0004
其中 R和 R,如权利要求 1所定义。 g) 利用 Mitsunobu反应使中间体 II与 2- J^-6-氯 -鸟嘌呤偶联得到化 合物 8, Wherein R and R are as defined in claim 1. g) coupling intermediate II with 2-J^-6-chloro-guanine using Mitsunobu reaction to give compound 8,
Figure imgf000050_0001
Figure imgf000050_0001
其中 R和 R,如权利要求 1所定义;  Wherein R and R are as defined in claim 1;
h)化合物 8在酸性 frfr 物  h) compound 8 in acidic frfr
Figure imgf000050_0002
Figure imgf000050_0002
47、权利要求 46的方法,其中,在步骤 c中,反应的催化剂为 Grubbs 第一代或第二代催化剂, 用量为 0.1~20 eq%。  47. The method of claim 46, wherein in step c, the catalyst for the reaction is Grubbs first or second generation catalyst in an amount of from 0.1 to 20 eq%.
48、 权利要求 46或 47的方法, 其中, 在步骤 d中, 使用金属钒的配 位试剂作为催化剂, 例如 VO(acac)2, 环氧化试剂选自叔丁基过氧化氢、 过氧化氢、 间氯过氧苯甲酸、 过氧苯甲酸、 过氧甲酸、 过氧乙酸。 48. The method of claim 46 or 47, wherein in step d, a coordination reagent of a metal vanadium is used as a catalyst, such as VO(acac) 2 , and the epoxidizing agent is selected from the group consisting of t-butyl hydroperoxide and hydrogen peroxide. , m-chloroperoxybenzoic acid, peroxybenzoic acid, peroxycarboxylic acid, peracetic acid.
49、 权利要求 46至 48任意一项所述的方法, 其中, 在步骤 e中, 在 化合物 4 的仲醇的保护试剂 RX 中, R选自 BnOCH2-、 MeOCH2-、 t-Bu(Me)2Si -、 i-Pr3Si-和 t-BuPh2Si-; X为卤素, 例如 C1; 反应中使用的 碱选自三乙胺、 二异丙基乙胺、 DBU、 咪唑等。 The method according to any one of claims 46 to 48, wherein, in the step e, in the protective reagent RX of the secondary alcohol of the compound 4, R is selected from the group consisting of BnOCH 2 -, MeOCH 2 -, t-Bu (Me 2 Si -, i-Pr 3 Si- and t-BuPh 2 Si-; X is a halogen such as C1; the base used in the reaction is selected from the group consisting of triethylamine, diisopropylethylamine, DBU, imidazole and the like.
50、 权利要求 46至 49任意一项所述的方法, 其中, 在步驟 f中, 二 烷基氯化铝试剂是例如二乙基氯化铝, N,N-二烷基胺裡由相应的二烷基胺 经与丁基锂反应原位制得, 其中二烷基胺选自 N,N-二异丙基胺、 N,N-二环 己基胺和 2,2,6,6-四甲基六氢吡啶。 50. The method of any one of claims 46 to 49, wherein in step f, the dialkylaluminum chloride reagent is, for example, diethylaluminum chloride, N,N-dialkylamine, by corresponding Dialkylamine Prepared in situ by reaction with butyllithium, wherein the dialkylamine is selected from the group consisting of N,N-diisopropylamine, N,N-dicyclohexylamine, and 2,2,6,6-tetramethylhexahydro Pyridine.
51、 权利要求 46至 50任意一项所述的方法, 其中, 在步骤 g 中, Mitsunobu反应试剂为膦催化剂如三苯基磷和偶氮二甲酸二乙酯或偶氮二 甲酸二异丙酯。  The method according to any one of claims 46 to 50, wherein, in the step g, the Mitsunobu reaction reagent is a phosphine catalyst such as triphenylphosphine and diethyl azodicarboxylate or diisopropyl azodicarboxylate. .
52、 权利要求 46至 51任意一项所述的方法, 其中, 在步骤 h中, 所 用的酸为无机酸, 例如盐酸、 硫酸。  The method according to any one of claims 46 to 51, wherein, in the step h, the acid used is a mineral acid such as hydrochloric acid or sulfuric acid.
53、 权利要求 46至 52任意一项所述的方法, 其中:  53. The method of any of claims 46 to 52, wherein:
在步骤 c中, 反应的催化剂为 Grubbs第一代或第二代催化剂, 用量 为 0.1 20 eq%;  In step c, the catalyst for the reaction is Grubbs first or second generation catalyst, and the amount is 0.120 eq%;
在步骤 d中, 使用金属钒的配位试剂作为催化剂, 例如 VO(acac)2, 环氧化试剂选自叔丁基过氧化氢、 过氧化氢、 间氯过氧苯甲酸、 过氧苯甲 酸、 过氧甲酸、 过氧乙酸; In step d, a coordination reagent of metal vanadium is used as a catalyst, such as VO(acac) 2 , and the epoxidizing agent is selected from the group consisting of t-butyl hydroperoxide, hydrogen peroxide, m-chloroperoxybenzoic acid, and peroxybenzoic acid. , peroxyformic acid, peracetic acid;
在步骤 e中,在化合物 4的仲醇的保护试剂 RX中, R选自 BnOCH2-、 MeOCH2-、 t-Bu(Me)2Si -、 i-Pr3Si-和 t-BuPh2Si-; X为卤素, 例如 C1; 反 应中使用的碱选自三乙胺、 二异丙基乙胺、 DBU、 咪峻等; In the step e, in the protective reagent RX of the secondary alcohol of the compound 4, R is selected from the group consisting of BnOCH 2 -, MeOCH 2 -, t-Bu(Me) 2 Si -, i-Pr 3 Si- and t-BuPh 2 Si - X is a halogen, such as C1; the base used in the reaction is selected from the group consisting of triethylamine, diisopropylethylamine, DBU, imi, and the like;
在步骤 f 中, 二烷基氯化铝试剂是例如二乙基氯化铝, N,N-二烷 锂由相应的二烷基胺经与丁基锂反应原位制得, 其中二烷基胺选自 N,N- 二异丙基胺、 N,N-二环己基胺和 2,2,6,6-四甲基六氢吡啶;  In step f, the dialkyl aluminum chloride reagent is, for example, diethylaluminum chloride, and the N,N-dialkyllithium is prepared in situ from the corresponding dialkylamine by reaction with butyllithium, wherein the dialkyl group The amine is selected from the group consisting of N,N-diisopropylamine, N,N-dicyclohexylamine, and 2,2,6,6-tetramethylhexahydropyridine;
在步骤 g中, Mitsunobu反应试剂为膦催化剂如三苯基磷和偶氮二甲 酸二乙酯或偶氮二甲酸二异丙酯;  In step g, the Mitsunobu reaction reagent is a phosphine catalyst such as triphenylphosphine and diethyl azodicarboxylate or diisopropyl azodicarboxylate;
在步骤 h中, 所用的酸为无机酸, 例如盐酸、 硫酸。  In step h, the acid used is a mineral acid such as hydrochloric acid or sulfuric acid.
54、 权利要求 46至 53中任意一项所述的方法, 其中用化合物 4作为 原料并进行其中所述的步骤 d)到 h)。  The method according to any one of claims 46 to 53, wherein the compound 4 is used as a raw material and the steps d) to h) described therein are carried out.
55、 权利要求 46至 53中任意一项所述的方法, 其中用化合物 5作为 原料并进行其中所述的步骤 e)到 h)。  The method according to any one of claims 46 to 53, wherein the compound 5 is used as a raw material and the steps e) to h) described therein are carried out.
56、 权利要求 46至 53中任意一项所述的方法, 其中用化合物 6作为 原料并进行其中所述的步骤 f)到 h)。 The method according to any one of claims 46 to 53, wherein the compound 6 is used as a raw material and the steps f) to h) described therein are carried out.
57、 制备权利要求 46的式 I化合物的方法, 57. A process for the preparation of a compound of formula I according to claim 46,
该方法包括以下步骤:  The method includes the following steps:
a) 中间体化合物 1经与异丙烯格氏试剂在卤化亚铜存在下反应得到化 合物 2  a) Intermediate compound 1 is reacted with isopropenol Grignard reagent in the presence of cuprous halide to obtain compound 2
Figure imgf000052_0001
Figure imgf000052_0001
其中 X为卤素或氰基,  Wherein X is a halogen or a cyano group,
b)将化合物 择性保护得化合 3,  b) selective compounding of the compound 3,
Figure imgf000052_0002
Figure imgf000052_0002
其中 R,如权利要求 46所定义, X为卤素,  Wherein R is as defined in claim 46, and X is a halogen,
c)将化合物 3在 Grubbs催化剂存在下, 经烯烃复分解反应得到环状 化合物 4,
Figure imgf000052_0003
c) the compound 3 is subjected to olefin metathesis reaction in the presence of a Grubbs catalyst to obtain a cyclic compound 4,
Figure imgf000052_0003
其中 R,如权利要求 46所定义,  Where R is as defined in claim 46,
d) 将化合物 4 与环氧化试剂在金属钒试剂催化下立体选择性地得到 环氧化中间体 5,
Figure imgf000052_0004
d) stereoselectively obtaining epoxidation intermediate 5 with compound 4 and an epoxidation reagent catalyzed by a metal vanadium reagent,
Figure imgf000052_0004
其中 R,如权利要求 46所定义, e)将化合物 5的Where R, as defined in claim 46, e) Compound 5
Figure imgf000053_0001
Figure imgf000053_0001
其中 X为卤素, R和 R,如权利要求 46所定义,  Wherein X is halogen, R and R, as defined in claim 46,
f)化合物 6在二烷基氯化铝试剂和 N,N-二烷基胺锂作用下环氧开环形 成中间体 II, f) compound 6 is epoxy-opened to form intermediate II under the action of a dialkylaluminum chloride reagent and lithium N,N-dialkylamine,
Figure imgf000053_0002
Figure imgf000053_0002
其中 R和 R,如权利要求 46所定义。  Wherein R and R are as defined in claim 46.
g) 利用 Mitsunobu反应使中间体 II与 2- J^-6-氯 -鸟嘌呤偶联得到化 合物 8,
Figure imgf000053_0003
g) coupling intermediate II with 2-J^-6-chloro-guanine using Mitsunobu reaction to give compound 8,
Figure imgf000053_0003
其中 R和 R,如权利要求 1所定义;  Wherein R and R are as defined in claim 1;
h)化合物 8在酸性 frfr下水解得到式 I化合物
Figure imgf000054_0001
h) Compound 8 is hydrolyzed under acidic frfr to give a compound of formula I
Figure imgf000054_0001
58、权利要求 57的方法,其中,在步骤 a中, 卤化亚铜试剂选自 Cul、 CuBr或 CuBr.Me2S; 58. The method of claim 57, wherein in step a, the cuprous halide agent is selected from the group consisting of Cul, CuBr or CuBr.Me 2 S;
59、 权利要求 57或 58的方法, 其中, 在步骤 b中, 伯羟基保护试剂 R,X选自三苯基氯化硅、 三异丙基氯化硅、 叔丁基二甲基氯化硅、 叔丁基 二苯基氯化硅、 三苯基氯甲烷, 碱为有 , 例如三乙胺、 DBU、 咪唑、 二异丙基乙胺。  59. The method of claim 57 or 58, wherein, in step b, the primary hydroxyl protecting agent R, X is selected from the group consisting of triphenylsilyl chloride, triisopropylsilyl chloride, tert-butyldimethylsilyl chloride , tert-butyldiphenylsilyl chloride, triphenylchloromethane, a base such as triethylamine, DBU, imidazole, diisopropylethylamine.
60、 权利要求 57-59任意一项的方法, 其中, 在步骤 c中, 反应的催 化剂为 Grubbs第一代或第二代催化剂, 用量为 0.1~20 eq%。  60. The process of any of claims 57-59, wherein in step c, the catalyst for the reaction is a Grubbs first or second generation catalyst in an amount of from 0.1 to 20 eq%.
61、 权利要求 57-60任意一项的方法, 其中, 在步骤 d中, 使用金属 钒的配位试剂作为催化剂, 例如 VO(acac)2, 环氧化试剂选自叔丁基过氧 化氢、 过氧化氢、 间氯过氧苯甲酸、 过氧苯甲酸、 过氧甲酸、 过氧乙酸。 The method according to any one of claims 57 to 60, wherein, in the step d, a coordination reagent of a metal vanadium is used as a catalyst, for example, VO(acac) 2 , and the epoxidizing agent is selected from t-butyl hydroperoxide, Hydrogen peroxide, m-chloroperoxybenzoic acid, peroxybenzoic acid, peroxycarboxylic acid, peracetic acid.
62、 权利要求 57-61任意一项所述的方法, 其中, 在步骤 e中, 在化 合物 4 的仲醇的保护试剂 RX 中, R 选自 BnOCH2-、 MeOCH2-、 t-Bu(Me)2Si -、 i-Pr3Si-和 t-BuPh2Si-; X为卤素, 例如 C1; 反应中使用的 碱选自三乙胺、 二异丙基乙胺、 DBU、 咪唑等。 The method according to any one of claims 57 to 61, wherein, in the step e, in the protective reagent RX of the secondary alcohol of the compound 4, R is selected from the group consisting of BnOCH 2 -, MeOCH 2 -, t-Bu (Me 2 Si -, i-Pr 3 Si- and t-BuPh 2 Si-; X is a halogen such as C1; the base used in the reaction is selected from the group consisting of triethylamine, diisopropylethylamine, DBU, imidazole and the like.
63、 权利要求 57-62任意一项所述的方法, 其中, 在步骤 f 中, 二烷 基氯化铝试剂是例如二乙基氯化铝, N,N-二烷基胺锂由相应的二烷基胺经 与丁基锂反应原位制得, 其中二烷基胺选自 N,N-二异丙基胺、 N,N-二环己 ^^和 2,2,6,6-四甲基六氢吡啶。  63. The method of any of claims 57-62, wherein in step f, the dialkylaluminum chloride reagent is, for example, diethylaluminum chloride, N,N-dialkylamine lithium from the corresponding The dialkylamine is prepared in situ by reaction with butyllithium, wherein the dialkylamine is selected from the group consisting of N,N-diisopropylamine, N,N-dicyclohexanyl and 2,2,6,6- Tetramethylhexahydropyridine.
64、权利要求 57-63任意一项所述的方法,其中,在步骤 g中, Mitsunobu 反应试剂为膦催化剂如三苯基磷和偶氮二甲酸二乙酯或偶氮二甲酸二异丙 酯。 64. The method of any of claims 57-63, wherein in step g, the Mitsunobu reagent is a phosphine catalyst such as triphenylphosphine and diethyl azodicarboxylate or diisopropyl azodicarboxylate. .
65、 权利要求 57-64任意一项所述的方法, 其中, 在步骤 h中, 所用 的酸为无机酸, 例如盐酸、 硫酸。 The method according to any one of claims 57 to 64, wherein in the step h, the acid used is a mineral acid such as hydrochloric acid or sulfuric acid.
66、 权利要求 57-65任意一项所述的方法, 其中:  66. The method of any of claims 57-65, wherein:
在步骤 a中, 卤化亚铜试剂选自 Cul、 CuBr或 CuBr.Me2S; In step a, the cuprous halide reagent is selected from Cul, CuBr or CuBr.Me 2 S;
在步骤 b中, 伯羟基保护试剂 R,X选自三苯基氯化硅、 三异丙基氯化 硅、 叔丁基二甲基氯化硅、 叔丁基二苯基氯化硅、 三苯基氯甲烷, 碱为有 机喊, 例如三乙胺、 DBU、 咪唑、 二异丙基乙胺;  In step b, the primary hydroxyl protecting agent R, X is selected from the group consisting of triphenylsilyl chloride, triisopropylsilyl chloride, tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride, three Phenylchloromethane, the base is organically called, such as triethylamine, DBU, imidazole, diisopropylethylamine;
在步骤 c中, 反应的催化剂为 Grubbs第一代或第二代催化剂, 用量 为 0.1 20 eq%;  In step c, the catalyst for the reaction is Grubbs first or second generation catalyst, and the amount is 0.120 eq%;
在步骤 d中, 使用金属钒的配位试剂作为催化剂, 例如 VO(acac)2, 环氧化试剂选自叔丁基过氧化氢、 过氧化氢、 间氯过氧苯甲酸、 过氧苯甲 酸、 过氧甲酸、 过氧乙酸; In step d, a coordination reagent of metal vanadium is used as a catalyst, such as VO(acac) 2 , and the epoxidizing agent is selected from the group consisting of t-butyl hydroperoxide, hydrogen peroxide, m-chloroperoxybenzoic acid, and peroxybenzoic acid. , peroxyformic acid, peracetic acid;
在步骤 e中,在化合物 4的仲醇的保护试剂 RX中, R选自 BnOCH2-、 MeOCH2-、 t-Bu(Me)2Si -、 i-Pr3Si-和 t-BuPh2Si-; X为卤素, 例如 C1; 反 应中使用的碱选自三乙胺、 二异丙基乙胺、 DBU、 咪峻等; In the step e, in the protective reagent RX of the secondary alcohol of the compound 4, R is selected from the group consisting of BnOCH 2 -, MeOCH 2 -, t-Bu(Me) 2 Si -, i-Pr 3 Si- and t-BuPh 2 Si - X is a halogen, such as C1; the base used in the reaction is selected from the group consisting of triethylamine, diisopropylethylamine, DBU, imi, and the like;
在步骤 f 中, 二烷基氯化铝试剂是例如二乙基氯化铝, N,N-二烷 锂由相应的二烷基胺经与丁基锂反应原位制得, 其中二烷基胺选自 N,N- 二异丙基胺、 N,N-二环己基胺和 2,2,6,6-四甲基六氢吡啶;  In step f, the dialkyl aluminum chloride reagent is, for example, diethylaluminum chloride, and the N,N-dialkyllithium is prepared in situ from the corresponding dialkylamine by reaction with butyllithium, wherein the dialkyl group The amine is selected from the group consisting of N,N-diisopropylamine, N,N-dicyclohexylamine, and 2,2,6,6-tetramethylhexahydropyridine;
在步骤 g中, Mitsunobu反应试剂为膦催化剂如三苯基磷和偶氮二甲 酸二乙酯或偶氮二甲酸二异丙酯;  In step g, the Mitsunobu reaction reagent is a phosphine catalyst such as triphenylphosphine and diethyl azodicarboxylate or diisopropyl azodicarboxylate;
在步骤 h中, 所用的酸为无机酸, 例如盐酸、 硫酸。  In step h, the acid used is a mineral acid such as hydrochloric acid or sulfuric acid.
67、 权利要求 57至 66中任意一项所述的方法, 其中用化合物 2作为 原料并进行其中所述的步骤 b)到 h)。  The method according to any one of claims 57 to 66, wherein the compound 2 is used as a raw material and the steps b) to h) described therein are carried out.
PCT/CN2013/072458 2012-03-12 2013-03-12 Synthetic intermediate of entecavir and method for preparing same WO2013135165A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210063329.3A CN103304375B (en) 2012-03-12 2012-03-12 Synthesis intermediate of Entecavir and preparation method thereof
CN201210063329.3 2012-03-12

Publications (1)

Publication Number Publication Date
WO2013135165A1 true WO2013135165A1 (en) 2013-09-19

Family

ID=49130137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/072458 WO2013135165A1 (en) 2012-03-12 2013-03-12 Synthetic intermediate of entecavir and method for preparing same

Country Status (2)

Country Link
CN (1) CN103304375B (en)
WO (1) WO2013135165A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105524064B (en) * 2014-09-30 2017-10-31 中国科学院广州生物医药与健康研究院 The synthetic method of Entecavir
CN105037363B (en) * 2015-07-13 2016-08-24 山东罗欣药业集团股份有限公司 A kind of entecavir compound prepared novel synthesis
CN106749255B (en) * 2016-11-12 2018-10-30 新昌县勤勉贸易有限公司 A kind of preparation method of antiviral medicinal entecavir intermediate
CN106749382B (en) * 2016-11-12 2019-01-15 嘉兴敏实机械有限公司 The preparation method of entecavir midbodies
CN107188786B (en) * 2017-05-31 2021-10-22 湖北远大生命科学与技术有限责任公司 Preparation method of optically pure cyclopentenol as medical intermediate
CN109705063B (en) 2017-10-26 2021-01-01 广州市朗启医药科技有限责任公司 Entecavir intermediate and synthetic method thereof, and synthetic method of entecavir
WO2019080686A1 (en) * 2017-10-26 2019-05-02 广州市朗启医药科技有限责任公司 Entecavir intermediate and synthesis method therefor, and method for synthesizing entecavir
CN109232637B (en) * 2018-10-29 2020-11-24 常州博海威医药科技股份有限公司 Preparation method of entecavir intermediate
CN112625041A (en) * 2020-12-25 2021-04-09 常州博海威医药科技股份有限公司 Novel preparation method and intermediate of entecavir

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009964A1 (en) * 1996-09-03 1998-03-12 Bristol-Myers Squibb Company IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE
CN1747959A (en) * 2002-12-11 2006-03-15 布里斯托尔-迈尔斯斯奎布公司 Process for preparing the antiviral agent [1s-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one
CN1964972A (en) * 2004-06-04 2007-05-16 布里斯托尔-迈尔斯斯奎布公司 Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN102596956A (en) * 2009-10-12 2012-07-18 韩美控股株式会社 Novel method for preparing entecavir and intermediate used therein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
CN101891741B (en) * 2010-07-06 2013-01-23 苏州汉德森医药科技有限公司 New synthesis process of antiviral drug entecavir

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009964A1 (en) * 1996-09-03 1998-03-12 Bristol-Myers Squibb Company IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE
CN1747959A (en) * 2002-12-11 2006-03-15 布里斯托尔-迈尔斯斯奎布公司 Process for preparing the antiviral agent [1s-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one
CN1964972A (en) * 2004-06-04 2007-05-16 布里斯托尔-迈尔斯斯奎布公司 Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN102596956A (en) * 2009-10-12 2012-07-18 韩美控股株式会社 Novel method for preparing entecavir and intermediate used therein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BISACCHI, GS. ET AL.: "BMS-200475, A Novel Carbocyclic 2'-Deoxyguanosine Analog with Potent and Selective Anti-Hepatitis B Virus Activity in Vitro", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 2, 1997, pages 127 - 132, XP004135980, DOI: doi:10.1016/S0960-894X(96)00594-X *
LIU, XIAOYU ET AL.: "A Novel and Efficient Synthesis of Entecavir", TETRAHEDRON LETTERS, vol. 53, no. 29, 18 July 2012 (2012-07-18), pages 3805 - 3807, XP028491280, DOI: doi:10.1016/j.tetlet.2012.05.058 *
ZHOU, BING ET AL.: "Synthesis of Entecavir (BMS-200475)", TETRAHEDRON LETTERS, vol. 53, 1 February 2012 (2012-02-01), pages 502 - 504, XP028346654, DOI: doi:10.1016/j.tetlet.2011.11.073 *
ZIEGLER, F.E. ET AL.: "Radical Cyclization Studies Directed Toward the Synthesis of BMS-200475 'Entecavir': the Carbocyclic Core", TETRAHEDRON, vol. 59, 2003, pages 9013 - 9018, XP004468316, DOI: doi:10.1016/j.tet.2003.02.001 *

Also Published As

Publication number Publication date
CN103304375A (en) 2013-09-18
CN103304375B (en) 2017-04-12

Similar Documents

Publication Publication Date Title
WO2013135165A1 (en) Synthetic intermediate of entecavir and method for preparing same
JP4726491B2 (en) Antiviral agent [1S- (1α, 3α, 4β)]-2-amino-1,9-dihydro-9- [4-hydroxy-3- (hydroxymethyl) -2-methylenecyclopentyl] -6H-purine-6 -Manufacturing method of ON
JP6573848B2 (en) Method for synthesizing entecavir and intermediate compound thereof
CN113354699B (en) Intermediate of Ruidexivir and preparation method thereof
JP4963968B2 (en) Process for producing 3-O-protected morphinone and 3-O-protected morphinone dienol carboxylate
JPS63310893A (en) Production of alkoxysilane
US8242288B2 (en) Method of preparing (6R)-3-hexyl-4-hydroxy-6-undecyl-5, 6-dihydropyran-2-one, and intermediate used in the method
JP3808735B2 (en) Intermediates for synthesizing vinblastine, methods for producing them, and methods for synthesizing vinblastine
US20110105780A1 (en) Method for obtaining polysulphide monoorganoxysilanes
JP6685386B2 (en) Organosilicon compound having (meth) acrylate group and method for producing the same
US7030243B1 (en) Process for making camptothecin derivatives
WO2018108130A1 (en) Process for preparation of novel androgen receptor antagonist
JP4701185B2 (en) Method for producing camptothecin derivative
TWI668220B (en) Synthetic method of entecavir and intermediate compounds thereof
JP4481255B2 (en) Compounds for the production of intermediates that synthesize vinblastine by coupling reaction with bindrin
JP4406406B2 (en) Intermediate for producing vinblastine by coupling reaction with bindrin
JP4520497B2 (en) Radiation-polymerizable functional group-containing organosilicon compound and method for producing the same
Hobson et al. Stereocontrolled syntheses of 2, 5-disubstituted tetrahydrofurans using remote asymmetric induction
WO2003031455A1 (en) Optically active dihydroxycyclohexane compounds and process for producing optically active hydroxyethylenedihydroxycycohexane compound
JPH05247043A (en) 2-bis(alkoxycarbonyl)methylidenepyrrolidine derivative
JP2012162512A (en) Method for producing hydroxysilyl ether compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13760335

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13760335

Country of ref document: EP

Kind code of ref document: A1